[
  {
    "section_code": "1.1",
    "condition": "The Concept of Emergency Care and Resuscitation ................................................. 31",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.3",
    "condition": "Approach to Stridor ....................................................................................................... 33",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "Approach to Seizure and Status Epilepticus .............................................................. 35",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.7",
    "condition": "Approach to Difficult in Breathing ............................................................................... 36",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.9",
    "condition": "Cardiac Tamponade ...................................................................................................... 38",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.11",
    "condition": "Approach to Shock ...................................................................................................... 39",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13",
    "condition": "Approach to Pain ................................................................................................. 43",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13.2",
    "condition": "Approach to Abdominal Pain .................................................................................. 44",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13.4",
    "condition": "Other Pains ................................................................................................................ 46",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.14",
    "condition": "Approach to Fever (Pyrexia) ............................................................................... 46",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.16",
    "condition": ". Approach to the Trauma Patient ....................................................................... 48",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.18",
    "condition": "Hyponatremia ....................................................................................................... 50",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.20",
    "condition": "Triage Overview ................................................................................................... 52",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.1",
    "condition": "General Anaesthesia ................................................................................................... 55",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.3",
    "condition": "Sedation .......................................................................................................................... 58",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4.1",
    "condition": "Surgery in Diabetic Patient ........................................................................................ 59",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4.3",
    "condition": "Surgery in Asthmatic Patient ..................................................................................... 60",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1",
    "condition": "Anaemia .......................................................................................................................... 62",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.2",
    "condition": "Megaloblastic Anemia ................................................................................................ 63",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.4",
    "condition": "Sickle Cell Disease (SCD) ........................................................................................ 64",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.5",
    "condition": "Aplastic Anaemia (Bone Marrow Failure) ............................................................... 68",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2",
    "condition": "Bleeding Disorders ..................................................................................................... 69",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2.1",
    "condition": "Hereditary Bleeding Disorders .................................................................................. 69",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.3",
    "condition": "Coagulation Disorders .................................................................................................. 72",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.3.2",
    "condition": "Pulmonary Embolism (PE) ......................................................................................... 73",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1",
    "condition": "Bacterial Infections ........................................................................................................ 77",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.2",
    "condition": "Anthrax ........................................................................................................................ 80",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.6",
    "condition": "Tick-Borne Relapsing Fever (TBRF) ......................................................................... 87",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2.1",
    "condition": "Viral Haemorrhaghic Fevers (VHF) ........................................................................... 88",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2.3",
    "condition": "Rabies .......................................................................................................................... 99",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2.5",
    "condition": "COVID-19 ................................................................................................................... 103",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.1",
    "condition": "Asymptomatic Malaria Case ....................................................................................... 109",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.2.1",
    "condition": "Uncomplicated Malaria .......................................................................................... 109",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.3",
    "condition": "Management of Malaria in Special Groups ............................................................... 114",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.3.2",
    "condition": "Management of Malaria in Neonates ....................................................................... 115",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1",
    "condition": "Treatment of HIV and AIDS in Adults and Adolescents ........................................... 117",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.2",
    "condition": "ART in women of childbearing potential or pregnant women .............................. 117",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.4",
    "condition": "Second-line ART in Adults and Adolescents ......................................................... 119",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2",
    "condition": "Changing Antiretroviral Therapy ................................................................................ 120",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.2",
    "condition": "Changing ART due to Treatment Failure ................................................................ 123",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.4",
    "condition": "Immune Reconstitution Inflammatory Syndrome (IRIS) .......................................... 124",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.7",
    "condition": "HIV Prevention ........................................................................................................... 132",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.7.2",
    "condition": "Pre-Exposure Prophylaxis (PrEP) ........................................................................... 133",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.1.1",
    "condition": "Drug Resistance Tuberculosis (DR-TB) ................................................................. 136",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.2",
    "condition": "General Treatment of Leprosy .................................................................................... 139",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1",
    "condition": "Infections of the Nervous System .............................................................................. 141",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.2",
    "condition": "Fungal Infections ...................................................................................................... 144",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.4",
    "condition": "Helminthic infections ............................................................................................... 146",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2",
    "condition": "Initial Management of Stroke ...................................................................................... 148",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2.2",
    "condition": "Initial Management of Acute Subarachnoid Hemorrhage from Ruptured Cerebral",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2.3",
    "condition": "Initial management of Acute Ischemic Stroke ....................................................... 150",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.5",
    "condition": "Congenital Pediatric Nervous System Diseases ...................................................... 155",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.5.2",
    "condition": "Management of Pediatric CSF shunt infections .................................................... 156",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.6",
    "condition": "Cranial Nerve Disorders .............................................................................................. 157",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.6.2",
    "condition": "Bell’s palsy ................................................................................................................ 158",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.7.1",
    "condition": "Acute Transverse Myelitis (TM) ............................................................................... 158",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.7.3",
    "condition": "Peripheral neuropathy .............................................................................................. 160",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.1",
    "condition": "Acute Respiratory Infections (ARI) ............................................................................ 162",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.1.1",
    "condition": "Pneumonia ................................................................................................................ 162",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.2.1",
    "condition": "Asthma ....................................................................................................................... 166",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.3",
    "condition": "Bronchitis ..................................................................................................................... 170",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.3.2",
    "condition": "Chronic Bronchitis ................................................................................................... 171",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.5",
    "condition": "COPD Exacerbation ..................................................................................................... 173",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.1",
    "condition": "Acute Laryngo-tracheobronchitis ........................................................................... 173",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.3",
    "condition": "Whooping Cough ...................................................................................................... 174",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.5",
    "condition": "Lung Abscess ........................................................................................................... 176",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.7",
    "condition": "Pneumocystis Pneumonia (PCP) ............................................................................ 177",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.11",
    "condition": "Obstructive sleep apnea syndrome (OSA ............................................................ 178",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.13",
    "condition": "Pleural effusion ....................................................................................................... 180",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.1",
    "condition": "Amoebiasis .............................................................................................................. 183",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.4",
    "condition": "Ascariasis ................................................................................................................ 184",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.6",
    "condition": "Strongyloidiasis ...................................................................................................... 185",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.7",
    "condition": "Taeniasis ................................................................................................................. 185",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.9",
    "condition": "Schistosomiasis ..................................................................................................... 186",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.11",
    "condition": "Shigellosis ............................................................................................................. 187",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.2.1",
    "condition": "Peptic Ulcer Disease .............................................................................................. 188",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.2.3",
    "condition": "Gastrointestinal (GI) Bleeding ............................................................................... 191",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.1",
    "condition": "Inflammatory Bowel Diseases ............................................................................... 194",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.3",
    "condition": "Radiation Proctitis .................................................................................................. 196",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.5",
    "condition": "Diverticulosis .......................................................................................................... 197",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.7",
    "condition": "Polyps and Adenomas ........................................................................................... 198",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.9",
    "condition": "Anal Fissures .......................................................................................................... 199",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.11",
    "condition": "Appendicitis .......................................................................................................... 200",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.1",
    "condition": "Acute Pancreatitis .................................................................................................. 201",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4",
    "condition": "Disorders of The Liver and Biliary Tract ............................................................... 202",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.2",
    "condition": "Portal Hypertension ................................................................................................ 209",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.1",
    "condition": "Bleeding in Pregnancy .............................................................................................. 217",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2",
    "condition": "Ectopic Pregnancy .................................................................................................... 222",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2.2",
    "condition": "Ruptured ectopic pregnancy ................................................................................. 222",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.3.1",
    "condition": "Placenta Praevia ..................................................................................................... 223",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.4",
    "condition": "Obstructed Labour .................................................................................................... 224",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.6",
    "condition": "Prelabour Rupture of Membranes (PROM) .............................................................. 226",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.1",
    "condition": "Anaemia in Pregnancy ........................................................................................... 227",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.3",
    "condition": "Pre-eclampsia ......................................................................................................... 228",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.5",
    "condition": "Eclampsia ................................................................................................................ 230",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.7",
    "condition": "Deep Vein Thrombosis in Pregnancy ................................................................... 232",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.9",
    "condition": "Vomiting in Pregnancy and Hyperemesis Gravidarum ....................................... 233",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.11",
    "condition": "Other Medical Disorders in Pregnancy ............................................................... 234",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.13",
    "condition": "Rhesus Incompatibility ........................................................................................ 236",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.1",
    "condition": "Mastitis .................................................................................................................... 236",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.4",
    "condition": "Dysmenorrhea ......................................................................................................... 239",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.9",
    "condition": "Contraception ............................................................................................................ 240",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.9.2",
    "condition": "Long term methods ................................................................................................ 241",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.4",
    "condition": "Infertility ................................................................................................................... 242",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.1",
    "condition": "STIs/RTIs Management Approaches ........................................................................ 244",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.3",
    "condition": "Vaginal Discharge Syndrome (VDS) ........................................................................ 245",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.5",
    "condition": "Painful Scrotal Swelling (PSS) ................................................................................. 247",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.7",
    "condition": "Oropharyngeal Syndrome ......................................................................................... 248",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.9",
    "condition": "Neonatal Conjunctivitis (Ophthalmia Neonatorum) ............................................... 249",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.8",
    "condition": "Management of other common STI Conditions .................................................... 260",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1",
    "condition": "Bacterial Skin Infections ........................................................................................... 262",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.2",
    "condition": "Folliculitis ................................................................................................................ 262",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.3",
    "condition": "Abscess ................................................................................................................... 263",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.5",
    "condition": "Paronychia .............................................................................................................. 264",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.1",
    "condition": "Tinea Corporis (Body Ringworm) ......................................................................... 265",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.3",
    "condition": "Pityriasis Versicolor ............................................................................................... 265",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.5",
    "condition": "Candidiasis .............................................................................................................. 266",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.7",
    "condition": "Chromoblastomycosis ........................................................................................... 267",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.3",
    "condition": "Parasitic Infestations ................................................................................................. 268",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4",
    "condition": "Viral Infections ........................................................................................................... 269",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.2",
    "condition": "Chickenpox ............................................................................................................. 269",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.4",
    "condition": "Post-herpetic Neuralgia ......................................................................................... 270",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.6",
    "condition": "Viral warts ................................................................................................................ 271",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5.1",
    "condition": "Contact Dermatitis .................................................................................................. 271",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5.3",
    "condition": "Seborrheic Dermatitis ............................................................................................ 273",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.7",
    "condition": "Papulosquamous Disorder ....................................................................................... 273",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.7.3",
    "condition": "Acne ......................................................................................................................... 275",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.8.1",
    "condition": "Fixed Drug Eruption (FDE) ..................................................................................... 276",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.10",
    "condition": "Pellagra ..................................................................................................................... 277",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.12",
    "condition": "Pruritic Papular Eruption (PPE) .............................................................................. 278",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.14",
    "condition": "Urticaria and Angioedema ...................................................................................... 279",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.17",
    "condition": "Keloids ...................................................................................................................... 281",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.19",
    "condition": "Infantile Haemangioma ........................................................................................... 282",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.21",
    "condition": "Skin Lightening ........................................................................................................ 282",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1",
    "condition": "Major Blinding Eye Diseases .................................................................................... 284",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.2",
    "condition": "Glaucoma ................................................................................................................ 286",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.4",
    "condition": "Diseases of the Retina ........................................................................................... 290",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2",
    "condition": "Painful Red Eyes ........................................................................................................ 296",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.2",
    "condition": "Herpes Simplex Keratitis ....................................................................................... 299",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.3",
    "condition": "Corneal Ulcer .......................................................................................................... 299",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.5",
    "condition": "Conjunctivitis .......................................................................................................... 301",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.4",
    "condition": "Ocular Oncology ........................................................................................................ 305",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.4.2",
    "condition": "Squamous Cell Carcinoma of Conjunctiva .......................................................... 307",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.6",
    "condition": "Herpes Zoster Ophthalmicus .................................................................................... 309",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.8",
    "condition": "Retinitis ....................................................................................................................... 310",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.10",
    "condition": "Visual Problems ....................................................................................................... 312",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1",
    "condition": "Ear Condition ............................................................................................................. 315",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.2",
    "condition": "Diffusewer Otitis Externa (Swimmer’s ear) .......................................................... 315",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.4",
    "condition": "Herpes Zoster Oticus (Ramsay Hunt syndrome) ................................................. 317",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2",
    "condition": "Trauma of the pinna .................................................................................................. 319",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2.2",
    "condition": "Laceration of the Pinna .......................................................................................... 319",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2.4",
    "condition": "Cerumen Impaction ................................................................................................ 320",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2.6",
    "condition": "Traumatic Tympanic Membrane/ Ear Drum Perforation. .................................... 320",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.3.1",
    "condition": "Acute Otitis Media .................................................................................................. 321",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.3.3",
    "condition": "Mastoditis with Sub-Periosteal Abscess .............................................................. 323",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4",
    "condition": "Hearing Loss .............................................................................................................. 324",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.2",
    "condition": "Sudden Sensorineural Hearing Loss .................................................................... 324",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.4",
    "condition": "Peripheral Vertigo (Meniere’s disease and Benign Paroxysmal Positional",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.5",
    "condition": "Vestibular Neuritis /Vestibular Neuronitis and Labyrinthitis .............................. 325",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.7",
    "condition": "Tinnitus .................................................................................................................... 326",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.9",
    "condition": "Vestibular schwannomas ....................................................................................... 327",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5.1",
    "condition": "Acute Rhinitis .......................................................................................................... 327",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5.3",
    "condition": "Allergic Rhinitis ...................................................................................................... 328",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.1",
    "condition": "Rhinoscleroma ........................................................................................................ 328",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.3",
    "condition": "Syphilis of the nose ................................................................................................ 329",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.5",
    "condition": "Mucormycosis ........................................................................................................ 330",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.1",
    "condition": "Nasal septal abscess and Hematoma ................................................................... 330",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.2",
    "condition": "Choanal atresia ...................................................................................................... 331",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.4",
    "condition": "Nasal bone fracture ................................................................................................ 331",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.6",
    "condition": "Adenoid Hypertrophy ............................................................................................. 332",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.8",
    "condition": "Chronic Rhinosinusitis .......................................................................................... 334",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.10",
    "condition": "Nose Bleeding (Epistaxis) .................................................................................... 335",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8",
    "condition": "Throat Conditions ...................................................................................................... 336",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.2",
    "condition": "Laryngitis ................................................................................................................. 337",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.4",
    "condition": "Chronic Laryngitis .................................................................................................. 338",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.6",
    "condition": "Non-infectious Chronic Laryngitis ........................................................................ 338",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.8",
    "condition": "Foreign Bodies in the Throat ................................................................................ 339",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.9",
    "condition": "Laryngomalacia ...................................................................................................... 340",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.11",
    "condition": "Infection of Thyroglossal duct cyst, dermoid cyst, branchial cleft cysts ....... 341",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.13",
    "condition": "Peritonsillar Abscess (Quincy) ............................................................................ 342",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.1",
    "condition": "Juvenile nasopharyngeal angiofibromas (JNA) .................................................. 343",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.3",
    "condition": "Parapharyngeal tumours ....................................................................................... 344",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.5",
    "condition": "Sino-Nasal Malignancy ........................................................................................... 344",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.7",
    "condition": "Oropharyngeal Malignancy .................................................................................... 346",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.9",
    "condition": "Metastatic Lymphadenopathy &Neck Masses ..................................................... 347",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1",
    "condition": "Periodontal Conditions ............................................................................................. 348",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1.2",
    "condition": "Periodontitis ............................................................................................................ 348",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1.4",
    "condition": "Stomatitis ................................................................................................................ 349",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3",
    "condition": "Odontogenic and Non-Odontogenic Orofacial Infections ..................................... 350",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.2",
    "condition": "Dental Abscess (Odontogenic Abscess) .............................................................. 351",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.4",
    "condition": "Pericoronitis ............................................................................................................ 352",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.4",
    "condition": "Fungal Infections ...................................................................................................... 353",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.5",
    "condition": "Viral Infections ........................................................................................................... 354",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.6",
    "condition": "Aphthous Ulceration ................................................................................................. 355",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7.1",
    "condition": "Bleeding socket ...................................................................................................... 355",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7.3",
    "condition": "Dry Socket ............................................................................................................... 356",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.8",
    "condition": "Tooth Sensitivities ..................................................................................................... 357",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.9.1",
    "condition": "Eruption of Teeth .................................................................................................... 357",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.9.3",
    "condition": "Edentulousness ...................................................................................................... 358",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.11",
    "condition": "Management of Maxillofacial Trauma .................................................................... 359",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.11.2",
    "condition": "Facial Bones Injuries ............................................................................................ 360",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.1",
    "condition": "Benign Odontogenic Tumors .............................................................................. 362",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.3",
    "condition": "Benign Soft Tissues Non-Odontogenic Tumours ............................................. 364",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.5",
    "condition": "Odontogenic and Non- Odontogenic Cysts ...................................................... 365",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14",
    "condition": "Temporal Mandibular Disorder and Chronic Orofacial Pain ............................... 367",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14.2",
    "condition": "Temporomandibular Disorders (TMDs) .............................................................. 368",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1",
    "condition": "Infections .................................................................................................................... 370",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1.2",
    "condition": "Septic arthritis ....................................................................................................... 371",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1.4",
    "condition": "Post Open reduction and internal fixation or arthroplasty infection ................ 371",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1.6",
    "condition": "Necrotizing fasciitis ............................................................................................... 373",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.1",
    "condition": "Rheumatoid Arthritis .............................................................................................. 374",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.4",
    "condition": "Osteoarthritis .......................................................................................................... 378",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.6",
    "condition": "Tendinopathies ....................................................................................................... 380",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.3",
    "condition": "Metabolic Bone Diseases ........................................................................................ 382",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.3.2",
    "condition": "Hypocholecalciferolemia (Vitamin D Deficiency) ............................................... 383",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.5",
    "condition": "Affection of the Brain and Spine ..............................................................................385",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.5.2",
    "condition": "Cervical Degenerative Disorders ......................................................................... 388",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.5.4",
    "condition": "Tuberculous spondylodiscitis .............................................................................. 391",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.6",
    "condition": "Common Congenital Anomalies of Musculoskeletal System .............................. 394",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.8",
    "condition": "Angular Deformity of Limbs ..................................................................................... 395",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.8.2",
    "condition": "Physiological Bowing/Knocked Knees ................................................................. 396",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.1",
    "condition": "Diabetes Mellitus ....................................................................................................... 397",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.2",
    "condition": "Management of Diabetes During Religious Fasting ............................................... 403",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.4",
    "condition": "Diabetes and HIV ....................................................................................................... 405",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.6",
    "condition": "Hypoglycaemia .......................................................................................................... 406",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.9",
    "condition": "Diabetic Peripheral Neuropathy ............................................................................... 411",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.11",
    "condition": "Diabetic Retinopathy ............................................................................................... 413",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.1",
    "condition": "Hypothyroidism .................................................................................................... 414",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.3",
    "condition": "Toxic Multinodular Goitre or Thyroid Antibody Positive .................................. 415",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.5",
    "condition": "Thyroid Storm (Crisis) .......................................................................................... 417",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.14",
    "condition": "Prolactinoma ............................................................................................................ 435",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.16",
    "condition": "Pheochromocytoma ................................................................................................ 436",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.8",
    "condition": "Obesity in Adults ....................................................................................................... 437",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.1",
    "condition": "Prevention of Atherosclerotic Ischaemic Heart Disease and Stroke .................... 441",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.3",
    "condition": "Chronic Stable Coronary Artery Disease (CSCAD) / ISCHAEMIC Heart Disease",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.4",
    "condition": "Acute Coronary Syndrome .................................................................................... 444",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.4.2",
    "condition": "Non-ST Elevation Myocardial Infarction (NSTEMI) .............................................. 444",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.5",
    "condition": "Hypertension .............................................................................................................. 447",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.7",
    "condition": "Hypertensive Urgency ............................................................................................... 454",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.9",
    "condition": "Heart Failure ............................................................................................................... 454",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.11",
    "condition": "Pulmonary Oedema ................................................................................................. 457",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.13",
    "condition": "Acute Rheumatic Fever ........................................................................................... 460",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.14.1",
    "condition": "Acute Pulmonary Embolism .............................................................................. 462",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15",
    "condition": "Cardiac Arrhythmias/ Dysrhythmias .................................................................... 464",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15.2",
    "condition": "AV Junctional Re-Entry Tachycardias .............................................................. 465",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.16",
    "condition": "Heart Block (Second & Third Degree) .................................................................. 467",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1",
    "condition": "Chronic Kidney Diseases (CKD) .............................................................................. 469",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.2",
    "condition": "Hypertension and CKD ........................................................................................... 471",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.4",
    "condition": "CKD Associated Metabolic Acidosis .................................................................... 473",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.5",
    "condition": "Hyperkalaemia ....................................................................................................... 473",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.8",
    "condition": "Haemodialysis (HD) Catheter Related Blood Stream Infection .......................... 475",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.3",
    "condition": "Glomerular Diseases (GD) ........................................................................................ 477",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.3.2",
    "condition": "Nephrotic syndrome ............................................................................................... 478",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.4.1",
    "condition": "Transplant Donor Evaluation ............................................................................... 481",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.4.3",
    "condition": "Transplant Recipient .............................................................................................. 483",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.5",
    "condition": "Cystic Kidney Disease .............................................................................................. 488",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.8",
    "condition": "Reflux nephropathy ................................................................................................... 489",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10",
    "condition": "Urinary Tract Infection (UTI) ................................................................................... 491",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.1",
    "condition": "Prostatitis .............................................................................................................. 493",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.3",
    "condition": "Prostate cancer .................................................................................................... 494",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.5",
    "condition": "Obstructive uropathy ........................................................................................... 496",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.11.1",
    "condition": "Female Sexual Dysfunction ................................................................................. 497",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.1",
    "condition": "Cancer Prevention, Screening and Early Detection ............................................... 499",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.1",
    "condition": "Cancer of the Uterine Cervix ................................................................................. 500",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.3",
    "condition": "Cancer of the Vulva ................................................................................................ 502",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.5",
    "condition": "Cancer of the Ovary ................................................................................................ 505",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.4",
    "condition": "Cancer of The Skin .................................................................................................... 508",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.4.2",
    "condition": "Malignant Melanoma .............................................................................................. 509",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5",
    "condition": "Head and Neck Cancers ............................................................................................ 510",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.2",
    "condition": "Laryngeal Cancer .................................................................................................... 511",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.4",
    "condition": "Salivary gland cancer ............................................................................................. 512",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.6",
    "condition": "Oral Cavity Cancer .................................................................................................. 512",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.8",
    "condition": "Thyroid Carcinoma ................................................................................................. 514",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.1",
    "condition": "Esophageal Cancer ................................................................................................ 515",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.3",
    "condition": "Hepatocellular Carcinoma ..................................................................................... 516",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.5",
    "condition": "Colon Cancer .......................................................................................................... 519",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.6",
    "condition": "Anal Cancer ............................................................................................................. 519",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.7.1",
    "condition": "Non-small cell lung Cancer .................................................................................... 520",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.8",
    "condition": "Genitourinary Malignancies ...................................................................................... 521",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.8.2",
    "condition": "Urinary Bladder Cancer .......................................................................................... 523",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.9.1",
    "condition": "Lymphomas ............................................................................................................. 524",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.9.3",
    "condition": "Multiple myeloma .................................................................................................... 528",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.10.1",
    "condition": "Meningiomas ......................................................................................................... 529",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.10.3",
    "condition": "Gliomas .................................................................................................................. 531",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.1",
    "condition": "Superior vena cava syndrome (SVCS) ............................................................... 533",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.3",
    "condition": "Spinal–cord Compression ................................................................................... 534",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.11.5",
    "condition": "Febrile Neutropenia .............................................................................................. 535",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.1",
    "condition": "Patients with Aggressive and Disruptive Behaviours ........................................... 537",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.4",
    "condition": "Schizophrenia ........................................................................................................... 539",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.6",
    "condition": "Schizoaffective Disorder .......................................................................................... 541",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.8",
    "condition": "Bipolar Mood Disorders ........................................................................................... 542",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.10",
    "condition": "Suicide ..................................................................................................................... 544",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.12",
    "condition": "Panic Disorder ........................................................................................................ 545",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.14",
    "condition": "Acute Stress Disorder and Post-Traumatic Stress   Disorder ............................ 547",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.15.1",
    "condition": "Substance Use Disorder ..................................................................................... 547",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.16",
    "condition": "Psychiatric Disorders Associated with Epilepsy ................................................. 552",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.17.1",
    "condition": "Depression ............................................................................................................ 554",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.17.3",
    "condition": "Obsessive-compulsive disorder ......................................................................... 555",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.19",
    "condition": "Attention Deficit / Hyperactivity Disorder (ADHD) ............................................... 557",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.21",
    "condition": "Neuroleptic Malignant Syndrome (NMS) .............................................................. 558",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.24",
    "condition": "Conversion Disorder .............................................................................................. 559",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.1",
    "condition": "Iodine Deficiency Disorders (IDD) ............................................................................ 560",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3",
    "condition": "Vitamin B Deficiencies .............................................................................................. 562",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3.3",
    "condition": "Vitamin B6/Pyridoxine Deficiency .......................................................................... 562",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.4",
    "condition": "Malnutrition ................................................................................................................ 563",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.6",
    "condition": "Obesity and Overweight ............................................................................................ 567",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.7.1",
    "condition": "Nutrient Requirements and Dietary Management in TB, HIV and AIDS Patients",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.8",
    "condition": "Dumping Syndrome. .................................................................................................. 569",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.10",
    "condition": "Nutrition Care and Support in the Intensive Care ................................................ 571",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.1",
    "condition": "Common poisons ...................................................................................................... 573",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.1",
    "condition": "Management Protocol of a poison (specific and non-specific antidotes) ......... 575",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.3",
    "condition": "Food Poisoning ....................................................................................................... 577",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.5",
    "condition": "Management of Skin contamination ..................................................................... 579",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.7",
    "condition": "Management of Inhaled Poisoning ....................................................................... 579",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.1",
    "condition": "Corrosive Compounds Poisoning ......................................................................... 580",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.3",
    "condition": "Organo-Phosphorus and Carbamate Compounds Poisoning ........................... 581",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.5",
    "condition": "Acetylsalicylic acid and other salicylates poisoning. ......................................... 585",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.7",
    "condition": "Carbon-monoxide Poisoning ................................................................................. 586",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.9",
    "condition": "Heavy Metal poisoning ........................................................................................... 587",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.5",
    "condition": "Alcohol Intoxication .................................................................................................. 589",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.6.1",
    "condition": "Management of Specific Bites/Stings ................................................................... 590",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.0",
    "condition": "Anasthetics, Preoperative Medicines and Medical Gases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.1.1",
    "condition": "Inhalational Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.1.2",
    "condition": "Injectable Medicines and Other Pre-Medication",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.2",
    "condition": "Local Anaesthetics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.3",
    "condition": "Muscle Relaxants and Cholinesterase Inhibitors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.0",
    "condition": "Medicines for Pain and Palliative Care",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.2",
    "condition": "Opioid Analgesics/Antagonists",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.3",
    "condition": "Medicines for Other Common Symptoms in Palliative Care",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "Anti-allergies and Medicines Used in Anaphylaxis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.0",
    "condition": "Antidotes and Other Substances Used in Poisonings",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2",
    "condition": "Antidotes (Specific)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.0",
    "condition": "Anticonvulsants and Antiepileptics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.0",
    "condition": "Anti-Infective Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.2",
    "condition": "Antifilariasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.3",
    "condition": "Anti-schistosomiasis and Other Anti-trematode Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2",
    "condition": "Antibacterial",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.2",
    "condition": "Watch Group Antibiotics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.3",
    "condition": "Reserve Group  Antibiotics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.3",
    "condition": "Antileprosy  Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.4",
    "condition": "Antituberculosis  Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.5",
    "condition": "Reserved Second-line for Treatment of Multidrug Resistance",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.3",
    "condition": "Antifungal Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.4",
    "condition": "Antiviral Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.4.2",
    "condition": "Antiretrovirals (ARVs)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.4.3",
    "condition": "Antihepatitis Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.5",
    "condition": "Antiprotozoal  Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.5.2",
    "condition": "Anti-malarial Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.5.3",
    "condition": "Malaria Prophylaxis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.0",
    "condition": "Antimigraine Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.2",
    "condition": "Medicines for Prophylaxis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.0",
    "condition": "Hormones and Antihormones",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.2",
    "condition": "Oestrogens",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.3",
    "condition": "Ovulation Inducers",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.4",
    "condition": "Progesterone",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.5",
    "condition": "Androgens",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6",
    "condition": "Contraceptives",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.7",
    "condition": "Thyroid, Parathyroid Hormones and Antagonists",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.1",
    "condition": "Antianaemia Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2",
    "condition": "Medicines Affecting Coagulation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.1",
    "condition": "Blood and Blood Components",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.2",
    "condition": "Plasma-Derived Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.2.2",
    "condition": "Blood Coagulation Factors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.3",
    "condition": "Plasma Substitutes",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.0",
    "condition": "Cardiovascular Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2",
    "condition": "Antiarrhythmic Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.0",
    "condition": "Blood Products of Human Origin and Plasma Substitute",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.3",
    "condition": "Antihypertensive Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4",
    "condition": "Medicines Used in Heart Failure",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5",
    "condition": "Diuretics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.6",
    "condition": "Antithrombotic Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.6.2",
    "condition": "Thrombolytics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.7",
    "condition": "Lipid Lowering Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.0",
    "condition": "Dermatological Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.3",
    "condition": "Anti-nflammatory and Anti-pruritic Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.4",
    "condition": "Medicines Affecting Skin differentiation and Proliferation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.5",
    "condition": "Scabicides and Pediculicides",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.6",
    "condition": "Sunscreen Protector",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2",
    "condition": "Anti-infective Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1",
    "condition": "Antiulcer Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2",
    "condition": "Drugs affecting Intestinal Secretion and Antispasmodics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.3",
    "condition": "Anti-emetics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4",
    "condition": "Cathartics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.0",
    "condition": "Gastro-Intestinal Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6",
    "condition": "Medicines Used in Diarrhoea",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.0",
    "condition": "Insulin and Medicines Used for Diabetes and Related Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.0",
    "condition": "Immunologicals",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5",
    "condition": "Anti-Haemorrhoids",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2",
    "condition": "Vaccines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.2",
    "condition": "For Specific Groups for Individuals",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "18.0",
    "condition": "Muscle Relaxants (Peripherally-Acting) and Cholinesterase Inhibitors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.5",
    "condition": "(metilsulfate)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.1",
    "condition": "Anti-infective Agents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.2",
    "condition": "Anti-allergy, Artificial Tears and Anti-inflammatory Agents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.3",
    "condition": "Local and Topical Ocular Anaesthetic Agents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.4",
    "condition": "Miotics and Antiglaucoma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.0",
    "condition": "Ophthamological Preparations",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.5",
    "condition": "Mydriatics and Anti-vascular Endothelial",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.6",
    "condition": "Other Ocular Preparations",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.0",
    "condition": "Oxytocics and Antioxytocics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.2",
    "condition": "Antioxytocics (tocolytics)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.0",
    "condition": "Dialysis Solution and Other Related Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.0",
    "condition": "Psychotherapeutic and Related Medicines",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2",
    "condition": "Medicines Used in Mood Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.2",
    "condition": "Medicines in Bipolar Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.3",
    "condition": "Medicines Used for anxiety Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.4",
    "condition": "Medicines Used for Disorders due to Psychoactive Substance use",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.0",
    "condition": "Medicines Acting on Respiratory Tract",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.2",
    "condition": "Cough Preparations",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.0",
    "condition": "Solutions, Correcting Water Electrolyte and Acid-Base Disturbances",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.0",
    "condition": "Vitamins/Minerals",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "26.0",
    "condition": "Medicines Used in Ear, Nose & Throat Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "26.2",
    "condition": "Oral Antiseptics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "26.3",
    "condition": "Nasal Preparations",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "27.0",
    "condition": "Disinfectants and Antiseptics",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "28.0",
    "condition": "Miscellaneous",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.1",
    "condition": "The Concept of Emergency Care and Resuscitation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.2",
    "condition": "Cardiac Arrest and Cardiopulmonary Resuscitation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.3",
    "condition": "Approach to Stridor",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.4",
    "condition": "Approach to Upper Gastrointestinal Bleeding",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "Approach to Seizure and Status Epilepticus",
    "definition": "",
    "investigations": [
      "Blood Glucose, Electrolytes: (Sodium, Potassium, Chloride, Magnesium and Calcium), ECG,",
      "Bedside ultrasound, Blood gases, Malaria Test, Serum creatinine and urea, Lactate levels,",
      "Pregnancy test (females), Toxicology screening and/orCT Head",
      "Non-pharmacological management",
      "•",
      "Protect patient from injury (If possible place in left lateral position to reduce aspiration",
      "risks), Don’t place tongue depressor",
      "•",
      "Perform both primary and secondary assessment and provide necessary interventions",
      "•",
      "Give Oxygen if needed",
      "•",
      "Do bedside random blood sugar test",
      "•",
      "Establish IV access for administration of anticonvulsants, if unable use the rectal route",
      "•",
      "Connect the patient to the cardiac monitor to obtain vital signs",
      "Pharmacological management",
      "I.",
      "Active seizure 0-5minutes",
      "Supportive care:",
      "IV access, monitors, maintain airway, oxygen therapy. Check point-of-care glucose and provide:",
      "A: dextrose 5%(IV); if glucose is ≤ 3.5mmol/L",
      "AND",
      "A: diazepam (IV) 0.15-0.2mg/kg. Maximum 10mg (Rectal dose: 0.2-0.5mg/kg) repeat",
      "every 5 minutes up to 3 doses",
      "OR",
      "D: midazolam (IV): 0.1mg/kg repeat every 5 minutes up to 3 doses",
      "II.",
      "Established Status Epilepticus 5-10 min",
      "B: phenobarbitone (IV):  Adults 20mg/kg slowly (max 50mg/min); Paediatrics 20mg/kg",
      "slowly (max 30mg/min)",
      "OR",
      "C: phenytoin (IV) Adults 20mg/kg slowly (max 50mg/min); Paediatrics 20mg/kg slowly",
      "(max 30mg/min)",
      "Consider INTUBATION if patient still seizing",
      "C: thiopental (IV):  Adult 3-6mg/kg loading dose then 25-100mg infusion as needed;",
      "Paediatrics 2-5mg/kg loading dose",
      "OR",
      "D: propofol (IV): Adults 2mg/kg loading dose then 2-10mg/kg/hour; Paediatrics 3mg/kg",
      "loading dose, then 7.5-18mg/kg/hr",
      "OR",
      "D: midazolam (IV): Adult 0.2mg/kg loading dose then 0.1-0.2mg/kg/hour; Paediatrics",
      "0.1mg/kg then infusion 0.06 – 0.4mg/kg/hour"
    ],
    "treatment": []
  },
  {
    "section_code": "1.6",
    "condition": "Approach to Altered Mental Status",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.7",
    "condition": "Approach to Difficult in Breathing",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.8",
    "condition": "Anaphylaxis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.9",
    "condition": "Cardiac Tamponade",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.10",
    "condition": "Pulmonary Edema",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.11",
    "condition": "Approach to Shock",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.12",
    "condition": "Sepsis and Septic Shock",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13",
    "condition": "Approach to Pain",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13.1",
    "condition": "Approach to Chest Pain",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13.2",
    "condition": "Approach to Abdominal Pain",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.13.4",
    "condition": "Other Pains",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.14",
    "condition": "Approach to Fever (Pyrexia)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.15",
    "condition": "Cough",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.16",
    "condition": ". Approach to the Trauma Patient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.17",
    "condition": "Approach to Dehydrated Patient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.18",
    "condition": "Hyponatremia",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Nutritional measures adjusted to patients need",
      "-",
      "Salt containing foods",
      "-",
      "Rehydration therapy",
      "-",
      "Dietary modification",
      "The goal of acute management is treatment of serious complications and careful restoration of",
      "serum sodium concentration. Management depends on the cause, severity and time course. Based",
      "on duration of development, hyponatremia can be (i) acute or (ii) chronic",
      "Table 1.4: Pharmacological Treatment for Hyponatremia",
      "ACUTE HYPONATREMIA",
      "CHRONIC HYPONATREMIA",
      "usually symptomatic and onset <48 hours"
    ]
  },
  {
    "section_code": "1.19",
    "condition": "Hypokalaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.20",
    "condition": "Triage Overview",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.1",
    "condition": "General Anaesthesia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.2",
    "condition": "Local Anaesthesia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.3",
    "condition": "Sedation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "Anaesthesiain Special Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4.2",
    "condition": "Surgery in Hypertensive Patient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4.3",
    "condition": "Surgery in Asthmatic Patient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4.4",
    "condition": "Surgery in Sickle Cell Patient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1",
    "condition": "Anaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.2",
    "condition": "Megaloblastic Anemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.3",
    "condition": "Haemolytic Anaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.4",
    "condition": "Sickle Cell Disease (SCD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.4",
    "condition": "G6PD Deficiency",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.5",
    "condition": "Aplastic Anaemia (Bone Marrow Failure)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.1.6",
    "condition": "Myelodysplastic syndrome (MDS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2",
    "condition": "Bleeding Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2.2",
    "condition": "Von Willebrand Disease (VWD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2.3",
    "condition": "Acquired Bleeding Disorders/Platelet Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.3",
    "condition": "Coagulation Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.3.1",
    "condition": "Deep Vein Thrombosis (DVT)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.3.2",
    "condition": "Pulmonary Embolism (PE)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.4",
    "condition": "Blood Transfusion",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1",
    "condition": "Bacterial Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.2",
    "condition": "Anthrax",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.3",
    "condition": "Plague",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.4",
    "condition": "Bacterial Cerebro-Spinal Meningitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.6",
    "condition": "milligrams per milliliter",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.2",
    "condition": "milligrams",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.5",
    "condition": "Neonatal Tetanus",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.1.6",
    "condition": "Tick-Borne Relapsing Fever (TBRF)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2",
    "condition": "Viral Infections",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Supportive therapy includes:",
      "•",
      "Mechanical ventilation, renal dialysis, and anti-seizure therapy may be required.",
      "•",
      "Management of complications symptomatically",
      "•",
      "Maintaining Oxygen status and Blood Pressure",
      "Pharmacological Treatment",
      "There is no specific treatment for Marburg Haemorrhagic Fever.",
      "A: paracetamol (PO/IV) 15mg/kg 8hourly for 3days",
      "B: Give oxygen and manage hypoglycaemia if present",
      "If there is Fluid and electrolyte imbalance:",
      "A: compound sodium lactate (Ringers Lactate), NS intravenously if cannot take fluids orally",
      "B: Give Oxygen therapy to maintain oxygen status.",
      "A: sodium lactate compound (Ringers Lactate), NS intravenously if cannot take fluids orally. Provide",
      "IV fluids and electrolytes (body salts) through infusion into the vein (intravenously)",
      "A: Manage hypoglycaemia with 5% DNS or 25% Dextrose Solution if hypoglycaemia is shown by",
      "RBG testing",
      "A: Using medication to support blood pressure, reduce vomiting and diarrhea and to manage fever",
      "and pain.",
      "A: Treating other infections or any complicating infection and co-morbid condition",
      "A: Psychological support is given to patient and family",
      "D: Refer for Provision of Mechanical ventilation, renal dialysis, and anti-seizure therapy may be",
      "required.",
      "4.2.1.3 Rift Valley Fever",
      "Rift Valley Fever (RVF) is a viral disease that affects mainly animals and occasionally humans. The",
      "virus is a member of the Phlebovirus genus, one of the five genera in the family Bunyaviridae. The",
      "disease is frequently reported following heavy rainfall and floods.  RVF is mainly transmitted from",
      "animals (sheep, cattle, goats, camels) to humans through close contact with infected animals (such",
      "as handling meat and body fluids and consumption of raw milk). During established RVF outbreaks",
      "in animals, humans can also get infected through bites of infected mosquitoes and other biting",
      "insects.",
      "92",
      "The incubation period of RVF varies from 2 to 6 days. These symptoms usually last from 4 to 7",
      "days. Most of the infected people recover on their own. However, a small proportion gets",
      "complications such as vomiting blood, nose bleeding and passing bloody stool. Rift Valley fever is",
      "difficult to distinguish from other viral haemorrhagic fevers as well as many other diseases that",
      "cause fever, including malaria, shigellosis, typhoid fever, and yellow fever.",
      "Case Definitions",
      "Suspected case: Early Disease:  Acute febrile illness (axillary temperature >37.5 ºC or oral",
      "temperature of >38.0ºC) of more than 48 hours’ duration that does not respond to antibiotic or",
      "antimalarial therapy, and is associated with:",
      "•",
      "Direct contact with sick or dead animal or its products AND / OR",
      "•",
      "Recent travel (during last week) to, or living in an area where, after heavy rains, livestock",
      "die or abort, and where RVF virus activity is suspected/confirmed AND / OR",
      "•",
      "Abrupt onset of any 1 or more of the following: exhaustion, backache, muscle pains,",
      "headache (often severe), discomfort when exposed to light, and nausea/vomiting AND /",
      "OR:",
      "•",
      "Nausea/vomiting, diarrhoea OR abdominal pain with 1 or more of the following:",
      "•",
      "Severe pallor (or Hb < 8 gm/dL)",
      "•",
      "Low platelets (thrombocytopenia) as evidence by presence of small skin and",
      "mucous membrane haemorrhages (petechiae) (or platelet count < 100x109 /",
      "d",
      "•",
      "Evidence of kidney failure (edema, reduced urine output) (or creatinine > 150",
      "mol/L) AND / OR",
      "•",
      "Evidence of bleeding into skin, bleeding from puncture wounds, from mucous",
      "membranes or nosefrom gastrointestinal tract and unnatural bleeding from",
      "vagina AND / OR",
      "•",
      "Clinical jaundice (3-fold increase above normal of transaminases)",
      "Late stages of diseases or complications",
      "(2-3 weeks after onset)",
      "•",
      "Patients who have experienced, in the preceding month a flu-like illness,",
      "with clinical criteria, who additionally develop the following:",
      "o",
      "CNS manifestations which resemble meningo-encephalitis AND/OR:",
      "o",
      "Unexplained visual loss OR",
      "o",
      "Unexplained death following sudden onset of acute flu-like",
      "illness with haemorrhage, meningo-ecephalitis, or visual loss",
      "during the preceding month.",
      "Confirmed case:",
      "Any patient who, after clinical screening, is positive for anti-RVF IgM ELISA",
      "antibodies (typically appear from fourth to sixth day after onset of symptoms) or",
      "tests positive on reverse transcriptase polymerase chainreaction (RT-PCR).",
      "Transmission to human is mainly through direct or indirect contact with blood or organs of infected",
      "animals. The virus can be transmitted to human through;",
      "•",
      "Handling of animal tissue during slaughtering or butchering, assisting with animal births,",
      "conducting veterinary procedures.",
      "•",
      "Inoculation e.g via wound from infected knife or through contact with broken skin or",
      "through inhalation of aerosols produced during the slaughter of an infected animals.",
      "•",
      "Infected mosquito.",
      "Human become viraemic; capable of infecting mosquitoes shortly before onset of fever and for the",
      "first 3–5 days of illness. Once infected, mosquitoes remain so for life.",
      "Clinical Diagnostic Criteria",
      "•",
      "Acute febrile illness that does notrespond to antibiotic or antimalarial therapy,",
      "•",
      "Exhaustion, backache, muscle pains, headache (often severe),",
      "•",
      "Photophobia",
      "•",
      "Nausea/vomiting",
      "•",
      "Evidence of bleeding into skin, bleeding from puncture wounds, from mucous membranes",
      "or nose, from gastrointestinal tract and unnatural bleeding from vagina",
      "93",
      "•",
      "Clinical jaundice (3-fold increase above normal of transaminases)",
      "Clinical diagnosis is difficult, because RVF symptoms can be mild and non-specific, especially early",
      "in the course of the disease.",
      "Laboratory Investigations",
      "Definitive diagnosis of RVF involves laboratory testing of blood (during illness) or other tissue",
      "samples (postmortem tissue).",
      "•",
      "The virus detection in the blood then virus isolation in cell culture",
      "•",
      "Molecular techniques (reverse transcriptase polymerase chain reaction or RT-PCR).",
      "•",
      "Antibody testing using Enzyme-Linked ImmunoAssay (ELISA) confirms infection with",
      "RVFV",
      "•",
      "IgM antibodies reflect a recent infection and IgG antibodies persist for several years",
      "(Detection of anti-RVF IgM suggests an ongoing transmission of RVFV in humans during",
      "inter-epidemic periods.).",
      "•",
      "FBC",
      "o",
      "Low Hb [Hb<8gm/dL - Severe pallor",
      "o",
      "Low platelet < 100 x109 /Dl (Thrombocytopenia) – small skin and mucous",
      "membrane hemorrhages (Petechiae))",
      "•",
      "Serum Creatinine",
      "Note",
      "Acute RVF can be diagnosed using several different methods",
      "1.",
      "Serological tests such as ELISA may confirm the presence of specific IgM antibodies",
      "to the virus. The virus itself may be detected in blood during the early phase of illness",
      "or in post-mortem tissue using a variety of techniques including, antigen detection",
      "tests by ELISA, RT-PCR, virus propagation (in cell cultures), Immunohistochemistry in",
      "formalin-fixed tissues",
      "2.",
      "ELISA IgG can be used for retrospective diagnostic.",
      "Management",
      "Management of RVF in humans is mainly supportive as there is no definitive treatment for RVF.",
      "Early detection and management of the disease is important. Human control of RVF is through",
      "control of the disease in animals through a sustained vaccination program and limiting human-",
      "animal contact. Use of insecticide treated nets and mosquito repellents can also reduce infections in",
      "human. In addition to human suffering and death, RVF has far reaching economic implications to the",
      "Livestock industry. In outbreak settings, the disease manifestation includes non-haemorrhagic",
      "febrile syndromes, and laboratory testing should be considered among persons with milder",
      "symptoms suggestive of viral illness.",
      "Prevention",
      "People living in or visiting areas with RVF shall be protected from the RVF infection with these",
      "steps:",
      "•",
      "Protect people from contact with blood, body fluids, or tissues of infected animals. (Use",
      "PPEs like gloves, boots, long sleeves, and a face shield)",
      "•",
      "Protect people from unsafe animal products. All animal products (including meat, milk, and",
      "blood) should be thoroughly cooked before eating or drinking.",
      "•",
      "Protect people from mosquitoes and other bloodsucking insects. Use insect repellents and",
      "bed nets, and wear long sleeved shirts and long pants to cover exposed skin.",
      "No vaccines are currently available for vaccination in people at risk of RVF infection.",
      "Public Health Control Measures",
      "•",
      "Mobilize the community for early detection and care.",
      "•",
      "Conduct community education about the confirmed case, how the disease is",
      "transmitted, and how to prevent contact with tissues of infected animals and avoid",
      "mosquito bites.",
      "•",
      "Provide information about prevention in the home and when to seek care.",
      "•",
      "Provide supportive treatment to all cases identified",
      "•",
      "Collaborate with the animal health specialists to search and document cases",
      "among animals as well.",
      "94",
      "4.2.1.4 Yellow Fever",
      "Yellow fever virus is an RNA that belongs to the genus Flavivirus and is related to West Nile, St.",
      "Louis encephalitis, and Japanese encephalitis viruses.  It is transmitted human-to-human via the",
      "domestic species of Aedes mosquitoes (Urban epidemics) or to humans from primate reservoir via a",
      "forest mosquito species (Sylvatic cycle). About 15% of infections progress to fever and jaundice.",
      "While only the minority of cases are severe, case fatality rate may be 25% to 50% among patients",
      "with syndrome of haemorrhage, jaundice, and renal disease. A small proportion of patients develop",
      "“toxic phase” with jaundice (yellowing of the skin and eyes, hence the name ‘yellow fever’), dark urine",
      "and abdominal pain with vomiting. Bleeding can occur from the mouth, nose, eyes or stomach and",
      "half of those die within 7 to 10 days.",
      "Risk factor: Sporadic cases often linked to occupation or village location near woods or where",
      "monkeys are numerous, also non-vaccinated persons. Infection and disease can be prevented",
      "by vaccination. With a vaccine efficacy > 95% and duration of immunity is life time",
      "Case definition",
      "Suspected case: Any person with acute onset of fever, with jaundice appearing within 14 days of",
      "onset of the first symptoms.",
      "Probable case: A suspected case with one of the following;",
      "•",
      "Epidemiological link to a confirmed case or an outbreak",
      "•",
      "Positive post-mortem liver histopathology",
      "Confirmed case: A probable case with one of the following;",
      "•",
      "Detection of YF-specific* IgM",
      "•",
      "Detection of four-fold increase in YF IgM and/or IgG antibody titres between",
      "acute and convalescent serum samples",
      "•",
      "Detection of YFV-specific* neutralizing antibodies",
      "*YF-specific means that antibody tests (such as IgM or neutralizing antibody) for other",
      "prevalent flavivirus are negative. This testing should include at least IgM for Dengue and",
      "West Nile and may include other flavivirus depending on local epidemiology.",
      "OR",
      "One of the following",
      "•",
      "Detection of YF virus genome in blood or other organs by PCR",
      "Detection of yellow fever antigen in blood, liver or other organs by immunoassays Isolation of the",
      "yellow fever virus",
      "Laboratory Investigations",
      "•",
      "ELISA for the presence of yellow fever Specific IgM and IgG antibodies.",
      "•",
      "Exclusion of Dengue, West Nile virus and other locally prevalent flavivirus will be",
      "necessary for the confirmation of yellow fever.",
      "•",
      "PCR, YF specific seroneutralization, virus isolation or histopathology",
      "Management",
      "Non-Pharmacological Treatment",
      "No specific anti-viral treatment, supportive therapies are recommended. Good and early supportive",
      "treatment for dehydration, liver and kidney failure, and fever improves outcomes. Associated",
      "bacterial infections can be treated with antibiotics",
      "Prevention",
      "Prevention and Control involve mosquito control and provision of Yellow Fever vaccine. The yellow",
      "fever vaccine is safe, affordable and a single dose provides life-long protection against yellow fever",
      "disease.",
      "Indication of Yellow Fever Vaccination",
      "•",
      "Persons ≥ 9 months of age",
      "•",
      "Planning travel to or residence in an endemic area",
      "•",
      "Planning travel to a country with an entry requirement",
      "Needs to be given ≥ 10 days prior to arrival in endemic area",
      "95",
      "Contraindications of Yellow Fever Vaccination",
      "•",
      "Infants aged less than 9 months;",
      "•",
      "Pregnant women – except during a yellow fever outbreak when the risk of infection is high;",
      "•",
      "People with severe allergies to egg protein; and",
      "People with severe immunodeficiency due to symptomatic HIV/AIDS or other causes, or",
      "who have a thymus disorder",
      "Public Health Control Measures",
      "•",
      "Identify all cases and provide clinical, epidemiological and laboratory evidences",
      "•",
      "Identify contacts, screen and test for confirmation",
      "•",
      "Educate the communities affected on mosquito control",
      "•",
      "Destroy known sources of standing water and any newly discovered sites for the presence",
      "of mosquito larvae.",
      "•",
      "Surveillance of Mosquito by Mosquito control professionals",
      "4.2.1.5 Dengue Fever",
      "Dengue virus is an arbovirus transmitted by aedes mosquitoes (both Ae. aegypti and Ae.",
      "albopiticus). Dengue fever is caused by four serologically distinct, but closely related Dengue",
      "viruses: dengue virus (DENV) 1, 2, 3, and 4 of the Flaviviridae family. Dengue fever is an emerging",
      "pandemic that has spread globally during the past 30 years as a result of changes in human",
      "ecology. Dengue haemorrhagic fever (DHF) is a potentially deadly complication that has become a",
      "leading cause of hospitalization and death among children in Asia and Africa. There is good",
      "evidence that sequential infection with the different serotypes of dengue virus increases the risk of",
      "more severe disease that can result in dengue shock syndrome (DSS) and death.",
      "Infected humans are the main carriers and multipliers of the virus, serving a source of the virus for",
      "uninfected Aedes aegypti mosquitoes which maintain the urban dengue transmission cycle. The",
      "virus circulates in the blood of infected human for 2-7 days, at approximately the same time that they",
      "have a fever. A sylvatic transmission cycle has been documented in West Africa where DENV-2 has",
      "been found in monkeys. There is no evidence of person-to-person transmission.",
      "DENV is frequently transported from one place to another by infected travelers; when susceptible",
      "vectors are present in these new areas, there is the potential for local transmission to be",
      "established.",
      "Case Definition",
      "Dengue Fever Suspected case: Any person with acute febrile illness of 2-7 days duration with 2 or",
      "more of the following: headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic",
      "manifestations, leucopenia.",
      "Dengue Fever Confirmed case: A suspected case with laboratory confirmation (positive IgM",
      "antibody, four-fold or greater rise in IgG antibody titres, positive PCR or viral isolation).",
      "Dengue Haemorrhagic Fever: A probable or confirmed case of dengue with bleeding tendencies",
      "as evidenced by one or more of the following: positive tourniquet test; petechieae, ecchymoses or",
      "purpura; bleeding: mucosa, gastrointestinal tract, injection sites or other; haematemesis or melaena;",
      "and thrombocytopenia (100,000 cells or less per mm3) and evidence of plasma leakage due to",
      "increased vascular permeability, manifested by one or more of the following: 20% rise in average",
      "haematocrit for age and sex, 20% drop in haematocrit following volume replacement therapy",
      "compared to baseline, signs of plasma leakage (pleural",
      "effusion, ascites, hypo-proteinaemia).",
      "Dengue Shock Syndrome: All the above criteria, plus evidence of circulatory failure manifested by",
      "rapid and weak pulse, and narrow pulse pressure (≤ 20 mm Hg) or hypotension for age, cold,",
      "clammy skin and altered mental status.",
      "Laboratory Investigations",
      "•",
      "Reverse Transcriptase–Polymerase Chain Reaction (RT–PCR)",
      "•",
      "Rapid Tests for Dengue NSI antigen",
      "Serological methods, such as Enzyme-Linked Immunosorbent Assays (ELISA) for IgM and IgG",
      "anti-dengue antibodiesFBP",
      "96",
      "Management",
      "There is no specific treatment for dengue, but appropriate medical care frequently saves the lives of",
      "patients with dengue haemorrhagic fever.",
      "Non-Pharmacological Treatment",
      "No specific treatment is available for Dengue fever.",
      "Pharmacological Treatment:",
      "A:  paracetamol (PO/IV) 15mg/kg 8hourly for 3days",
      "A: Maintainance fluid (Ringers lactate, NS) intravenously if one cannot take enough fluid orally",
      "B: Blood transfusion and clotting factors.",
      "B: Oxygen and manage hypoglycaemia if present",
      "Note",
      "•",
      "No antibiotics are of proven value.",
      "•",
      "Children below 12 years require close monitoring for dangerous form.",
      "•",
      "Steroids should not be used.",
      "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and aspirin should",
      "be avoided. These anti-inflammatory drugs act by thinning the blood, and in a disease",
      "with risk of hemorrhage, blood thinners may exacerbate the prognosis",
      "Prevention",
      "At present, the only method of controlling or preventing dengue virus transmission is to",
      "combat the vector mosquitoes using environmental management and chemical methods.",
      "•",
      "Prevent",
      "dengue",
      "by avoiding",
      "mosquito",
      "bites",
      "by",
      "Aedes.",
      "aegypti and Aedes.",
      "albopictus bite during the day and night (Using mosquito repellant, bed nets and",
      "removing reservoirs).",
      "•",
      "All",
      "four",
      "dengue",
      "viruses",
      "are",
      "spread",
      "primarily",
      "through",
      "the",
      "bite",
      "of",
      "an",
      "infected Aedes mosquito.",
      "•",
      "A dengue vaccine is available for use in some parts of the world",
      "Public Health Control Measures",
      "•",
      "Wear full sleeve clothes and long dresses to cover the limbs",
      "•",
      "Use mosquito repellents",
      "•",
      "Use mosquito nets – to protect babies, old people and others, who may rest during the",
      "day. Effectiveness of such nets can be improved by treating them with permethrin",
      "(pyrethroid insecticide). Curtains (cloth or bamboo) can also be treated with insecticide and",
      "hung at windows or doorways, to repel or kill mosquitoes",
      "4.2.1.6 Chikungunya Fever",
      "Chikungunya Virus Disease is the arthropod-borne virus caused by Chikungunya Virus (CHIKV),",
      "transmitted by the Aedes aegyptiand Aedes albopictus mosquitos the same which transmit Dengue",
      "virus, West Nile and Yellow Fever viruses. Chikungunya disease (Seroprevalance 7.7% to 26.9% in",
      "Tanzania) does not often result in death, but the symptoms can be severe and disabling. People at",
      "risk for more severe disease include newborns, older adults (≥65 years), and people with medical",
      "conditions such as high blood pressure, diabetes, or heart disease. The word \"Chikungunya\" is",
      "Makonde for \"that which bends up,\" in reference to the stooped posture of patients afflicted with the",
      "severe joint pain associated with the disease. Epidemics of fever, rash and arthritis, resembling",
      "Chikungunya fever were recorded as early as 1779. However, the virus was first isolated between",
      "1952-1953 from both man and mosquitoes during an epidemic in Tanzania.",
      "Case Definition",
      "Acute clinical case",
      "•",
      "Clinical criterion: Fever >38.50 C (101.30F) and joint paina (usually incapacitatingb) with",
      "acute onseta AND",
      "•",
      "Epidemiological criterion: resident or visitor in areas with local transmission of",
      "Chikungunya on the last 15 days (suspected case for epidemiological surveillance) b OR",
      "•",
      "Laboratory criterion: confirmation by laboratory: PCR, serology or viral culture (confirmed",
      "case for epidemiological surveillance)",
      "97",
      "•",
      "Usually accompanied by exanthema, myalgia, back pain, headache and, occasionally,",
      "vomiting and diarrhoea (pediatric age group).",
      "•",
      "In children aged <3 years, joint pain is expressed as inconsolable crying, irritability,",
      "rejection to mobilization and/or walking",
      "Atypical case",
      "Clinical case of laboratory confirmed Chikungunya accompanied by other manifestations:",
      "neurological, cardiological, dermatological, ophthalmological, hepatic, renal, respiratory, or",
      "haematological, among others.",
      "Severe acute case",
      "Clinical case of laboratory-confirmed Chikungunyapresenting dysfunction of at least one organ or",
      "system that threatens life and requires hospitalization",
      "Suspected and confirmed chronic cases",
      "Suspect chronic case: Person with previous clinical diagnosis of chikungunya after 12 weeks of the",
      "onset of the symptoms presenting with at least one of the following articular manifestations: pain,",
      "rigidity, or edema, continuously or recurrently.",
      "Confirmed chronic case: Every chronic case with a positive chikungunya laboratory test",
      "Laboratory Investigations",
      "Chikungunya is a biosafety level-3 (BSL-3)",
      "•",
      "Detection of Chikungunya virus (CHIKV) viral culture of blood in the first 3 days",
      "•",
      "RT-PCR for Viral RNA from the serum collected <6 days after onset of illness.",
      "Serological tests show a four-fold rise in antibody titer to Chikungunya virus;",
      "Non-Pharmacological Treatment:",
      "The mainstay treatment for Chikungunya is the supportive symptomatic treatment.",
      "A: Assure plenty of rest to patients",
      "Pharmacological Treatment",
      "A: Maintain body fluids Sodium Lactate Compound (Ringers Lactate) intravenously.",
      "A: Control Fever and Pain by giving paracetamol (PO/IV]15mg/kg 8hourly for 3days",
      "Note",
      "•",
      "No antibiotics are of proven value.",
      "•",
      "Steroids should not be used.",
      "•",
      "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and aspirin should",
      "be avoided. These anti-inflammatory drugs act by thinning the blood, and in a disease",
      "with risk of hemorrhage, blood thinners may exacerbate the prognosis",
      "•",
      "Do not use products containing oil of lemon eucalyptus (OLE) or para-menthane-diol",
      "(PMD) on children under 3 years old.",
      "•",
      "Do not apply insect repellent to a child’s hands, eyes, mouth, cuts, or irritated skin",
      "Prevention",
      "The most effective way to prevent infection from Chikungunya virus is to prevent mosquito bites",
      "during the day and night.",
      "•",
      "Use insect repellent (DEET, Picaridin (known as KBR 3023 and icaridin IR3535, Oil of",
      "lemon eucalyptus (OLE), Para-menthane-diol (PMD), 2-undecanone)",
      "•",
      "Modification of the mosquito bleeding sites",
      "•",
      "Wear long-sleeved shirts and pants,",
      "•",
      "Treat clothing and gears with permethrin",
      "•",
      "Take steps to control mosquitoes indoors and outdoors",
      "Public Health Control Measures",
      "•",
      "Symptomatic treatment for mitigating pain and fever using non-steroidal anti-inflammatory",
      "drugs along with rest usually suffices. Persistent joint pain may require analgesic and long-",
      "term anti-inflammatory therapy.",
      "•",
      "Prevention is entirely dependent upon taking steps to avoid mosquito bites and elimination",
      "of mosquito breeding sites.",
      "98",
      "•",
      "To avoid mosquito bites:",
      "o",
      "Wear full sleeve clothes and long dresses to cover the limbs",
      "o",
      "Use mosquito repellents",
      "o",
      "Use mosquito nets – to protect babies, old people and others, who may rest",
      "during the day.",
      "o",
      "The effectiveness of such nets can be improved by treating them with permethrin",
      "(pyrethroid insecticide). Curtains (cloth or bamboo) can also be treated with",
      "insecticide and hung at windows or doorways, to repel or kill mosquitoes"
    ]
  },
  {
    "section_code": "4.2.2",
    "condition": "Measles (Rubeola)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2.3",
    "condition": "Rabies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.6",
    "condition": "g/day",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "4.2.4",
    "condition": "Zika Virus Disease",
    "definition": "",
    "investigations": [],
    "treatment": [
      "The mainstay treatment for Zika Virus is the supportive symptomatic treatment.",
      "•",
      "A: Assure plenty of rest to patients",
      "Pharmacological Treatment",
      "•",
      "A: Maintain body fluids Sodium Lactate Compound (Ringers Lactate) intravenously.",
      "•",
      "A: Control Fever and Pain by giving Acetaminophen or Paracetamol 15mg/kg (PO/IV) 8",
      "hourly for 3 days",
      "Note",
      "•",
      "No antibiotics are of proven value.",
      "•",
      "Steroids should not be used.",
      "•",
      "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and aspirin should be",
      "avoided. These anti-inflammatory drugs act by thinning the blood, and in a disease with",
      "risk of hemorrhage, blood thinners may exacerbate the prognosis",
      "•",
      "Do not use products containing oil of lemon eucalyptus (OLE) or para-menthane-diol",
      "(PMD) on children under 3 years old.",
      "•",
      "Do not apply insect repellent to a child’s hands, eyes, mouth, cuts, or irritated skin",
      "Prevention",
      "•",
      "Vector control: - removal and modification of breeding sites and reducing contact between",
      "mosquitoes and people",
      "•",
      "Wearing clothing (preferably light-coloured) that covers as much of the body as possible;",
      "•",
      "Using physical barriers such as window screens and closed doors and windows;",
      "•",
      "Applying insect repellent to skin or clothing that contains DEET, IR3535 or icaridin",
      "Public Health Control Measures",
      "•",
      "Strengthen event-based surveillance to detect the emergence of clusters of cases",
      "presenting with rash and febrile syndrome of unknown aetiology.",
      "•",
      "Actively engage other sectors (e.g., environment, agriculture, tourism) to respond to Zika",
      "virus through a multi-sectoral approach (One Health approach).",
      "•",
      "Enhance surveillance of Zika virus disease and of the conditions that may be associated",
      "with it, including microcephaly and congenital Zika syndrome and Guillain-Barré syndrome",
      "(GBS).",
      "•",
      "Enhance surveillance at prenatal and postnatal clinics to monitor possible congenital",
      "infections and complications.",
      "•",
      "Conduct community-based assessments to determine the abundance of vector",
      "mosquitoes, identify the most productive larval habitats, promote and implement plans for",
      "appropriate vector control.",
      "•",
      "Report any identified unusual increase in the incidence of congenital neurological",
      "malformations including microcephaly in neonates and adverse pregnancy outcomes not",
      "explained through alternate causes, to the relevant public health authorities using IDSR",
      "framework.",
      "•",
      "Intensify of efforts to reduce mosquito populations including elimination of potential",
      "breeding sites (e.g., removal of trash and standing water sites around homes, covering",
      "home water storage containers, and use of larvicides) and adult mosquito control methods.",
      "•",
      "Promotion of personal protection measures such as use of light-coloured protective",
      "clothing (long sleeves and pants), insect repellent, and physical barriers such as screens,",
      "closed doors and windows, and sleeping under mosquito nets including during the day",
      "when Aedes mosquitoes are most active.",
      "•",
      "Develop risk communication messages to address population concerns, enhance",
      "community engagement, improve reporting, and ensure application of vector control and",
      "personal protective measures targeting reduction of contact with the vector.",
      "103",
      "•",
      "Provide women of childbearing age and particularly pregnant women with the necessary",
      "information and materials on family planning and to reducing risk of exposure.",
      "•",
      "Provide clinical and psychosocial support services for affected children and families.",
      "•",
      "Zika can be transmitted through blood and blood products. Precautions already in place for",
      "ensuring safe blood donations, transfusions, and prevention of bloodborne pathogens",
      "should be followed.",
      "•",
      "Zika can be transmitted sexually. Men and women need to get counselling on safer sexual",
      "practices, and be offered condoms and full range of contraceptive methods.",
      "•",
      "Ensure that pregnant women who have been exposed to Zika virus be counselled and",
      "followed for birth outcomes based on the best available information and national practice",
      "and policies.",
      "•",
      "Refer most severe cases with complication to hospitalized cares."
    ]
  },
  {
    "section_code": "4.2.5",
    "condition": "COVID-19",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.1",
    "condition": "Asymptomatic Malaria Case",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.2",
    "condition": "Symptomatic Malaria Case",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.2.2",
    "condition": "Severe Malaria",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "mg/kg in body weight. (IV) or (IM) given on admission (time = 0 hour), then at 12 hours",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.5",
    "condition": "1",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.5",
    "condition": "1",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.5",
    "condition": "5",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "3",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "1.5",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "2",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "4",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "5",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "6",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "6",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "7",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "8",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "9",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "10",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "11",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "12",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "13",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "14",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "15",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "16",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "17",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "18",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "19",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "20",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "21",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "22",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "23",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.4",
    "condition": "24",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.2",
    "condition": "mg/Kg",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.6",
    "condition": "mg/kg",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.2",
    "condition": "8",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.3",
    "condition": "13",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.5",
    "condition": "19",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.6",
    "condition": "26",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.8",
    "condition": "32",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.0",
    "condition": "40",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.2",
    "condition": "46",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.3",
    "condition": "53",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "59",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.6",
    "condition": "66",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.8",
    "condition": "72",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.0",
    "condition": "80",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.3",
    "condition": "Management of Malaria in Special Groups",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.3.2",
    "condition": "Management of Malaria in Neonates",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "5.3.3",
    "condition": "Management of Malaria in HIV and AIDS Patients",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1",
    "condition": "Treatment of HIV and AIDS in Adults and Adolescents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.1",
    "condition": "First-Line Regimens for Adults and Adolescents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.2",
    "condition": "ART in Women of Childbearing Potential or Pregnant Women",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.3",
    "condition": "Prevention of Mother to Child Transmission",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.4",
    "condition": "Second-line ART in Adults and Adolescents",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.1.5",
    "condition": "Third-line Antiretroviral Therapy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2",
    "condition": "Changing Antiretroviral Therapy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.2.2",
    "condition": "Changing ART due to Treatment Failure",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.3",
    "condition": "Monitoring Patients on Antiretroviral Therapy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.4",
    "condition": "Immune Reconstitution Inflammatory Syndrome (IRIS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.5",
    "condition": "Antiretroviral Therapy in Children and Adolescents Living with HIV",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.7",
    "condition": "HIV Prevention",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.7.2",
    "condition": "Pre-Exposure Prophylaxis (PrEP)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.1.1",
    "condition": "Drug Resistance Tuberculosis (DR-TB)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.1.2",
    "condition": "Treatment of Tuberculosis in Special Cases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.2",
    "condition": "General Treatment of Leprosy",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Day 2–28, Clofazimine 50mg + Dapsone",
      "100mg",
      "12 blister packs to be taken",
      "within a period of between",
      "12–18 months",
      "Child",
      "MB:",
      "below 15years",
      "Day 1: Rifampicin 450mg (3 x 150mg) + Clofazimine",
      "150mg (3 x 50mg) + Dapsone 50mg. Daily Treatment:",
      "Day 2–28 Clofazimine 50mg every other day +",
      "Dapsone 50mg daily.",
      "12 blister packs to be taken",
      "within a period of between",
      "12–18 months",
      "Adult",
      "PB:",
      "15years",
      "and",
      "above",
      "Day 1: Rifampicin 600mg (2x 300mg) +Clofazimine",
      "300mg (3 x 100mg) + Dapsone 100mg. Daily"
    ]
  },
  {
    "section_code": "7.2.1",
    "condition": "Treatment of Leprosy in Special Cases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1",
    "condition": "Infections of the Nervous System",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.1",
    "condition": "Bacterial infections",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Control fever and pain with IV Paracetamol",
      "•",
      "Manage seizures with antiepileptic drugs",
      "•",
      "Prompt initiation of intravenous antibiotics",
      "•",
      "Steroids in selected case",
      "144",
      "Table 8.2: Pharmacological management of Brain abscess",
      "Condition",
      "Treatment",
      "Duration",
      "Brain abscess",
      "(unspecific bacterial)",
      "A: benzyl penicillin (I.V) 5MU 6hourly",
      "OR",
      "C: amoxicillin +clavulanate (FDC) (IV) 1.2g 12hourly",
      "OR",
      "D: ceftriaxone+sulbactam (FDC) (IV) 1.5g 12hourly",
      "AND",
      "A: metronidazole (IV) 500mg 8 hourly",
      "alternative regimen based on C/S results",
      "S: piperacillin+tazobactam (FDC) (IV) 4.5g 8hourly",
      "OR",
      "S: meropenem (IV) 2g every 8hourly",
      "4-6weeks",
      "4-6 weeks",
      "2weeks",
      "2weeks",
      "Brain abscess (Staph.",
      "aureus)",
      "S: vancomycin (IV) 1g 12hourly (used",
      "with cefotaxime or ceftriaxone+Sulbactam)",
      "4-6weeks",
      "Seizures control",
      "C: phenytoin (IV) 15mg/kg loading dose infused at",
      "50mg/min followed by 100mg (IV/PO) 8hourly",
      "OR",
      "A: carbamazepine (PO/NGT) 200mg 12hourly",
      "OR",
      "C: sodium valproate (PO) 250mg 12hourly (escalate",
      "dose as required based on response)",
      "Until seizure",
      "free for at least",
      "6 months",
      "ICP control in selected",
      "cases",
      "B: dexamethasone (IV) 0.15mg/kg 6hourly",
      "3-5days"
    ]
  },
  {
    "section_code": "8.1.2",
    "condition": "Fungal Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.3",
    "condition": "Protozoa infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.4",
    "condition": "Helminthic infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.1.5",
    "condition": "Viral infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2",
    "condition": "Initial Management of Stroke",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2.2",
    "condition": "Initial Management of Acute Subarachnoid Hemorrhage from Ruptured",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.2.3",
    "condition": "Initial management of Acute Ischemic Stroke",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.3",
    "condition": "Management of Epilepsy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.5",
    "condition": "Congenital Pediatric Nervous System Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.5.2",
    "condition": "Management of Pediatric CSF Shunt Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.5.3",
    "condition": "Congenital Spina Bifida",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.6",
    "condition": "Cranial Nerve Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.6.2",
    "condition": "Bell’s Palsy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.7",
    "condition": "Spinal Cord and Peripheral Nerve Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.7.2",
    "condition": "Guillan Barre Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "8.7.3",
    "condition": "Peripheral Neuropathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.1",
    "condition": "Acute Respiratory Infections (ARI)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.1.1",
    "condition": "Pneumonia",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Oxygen therapy if available",
      "•",
      "Supportive care",
      "o",
      "Remove clothes",
      "o",
      "If wheezing giving rapid-acting bronchodilator: Nebulized Salbutamol",
      "o",
      "Ensure that the child receives daily maintenance fluid appropriate for the child’s age",
      "but avoid over-hydration refer to IMCI/ STG & Essential Medicines List for Children",
      "Pharmacological Treatment",
      "Non-severe pneumonia",
      "A: amoxicillin (PO) 25mg/kg 8hourly for 5days",
      "AND",
      "A: paracetamol (PO) 15mg/kg 8hourly for 5days(if fever present)",
      "OR",
      "A: paracetamol (supp) 10–15mg/kg (if there is fever)",
      "OR",
      "A: ibuprofen (PO) 15mg/kg 12hourly for 5days",
      "Give the first dose at the clinic and teach the mother how to give the other doses at home.",
      "Encourage breasting and feeding.",
      "Severe Pneumonia",
      "A: benzyl penicillin (IV/IM) 50000 units/kg every 6hours for at least 3days",
      "THEN",
      "A: amoxicillin (PO) 40 mg/kg 8hourly for 7days.",
      "Alternatively",
      "A: ampicillin (IV/IM) 50 mg/kg every 6hourly for 5days",
      "AND",
      "A: gentamicin (IV/IM) 7.5 mg/kg 24hourly for 5days",
      "THEN",
      "A: amoxicillin (PO) 40 mg/kg 8hourly for 7days.",
      "Note",
      "•",
      "For children above 5 years, atypical pneumonia should be considered e.g. mycoplasma",
      "•",
      "Consider alternative diagnosis after three visit /not responding, refer patient to a",
      "pediatrician",
      "9.1.1.2 Pneumonia in Adults",
      "Community Acquired Pneumonia",
      "CAP refers to a pneumonia that is acquired outside hospital commonly caused by Streptococcus",
      "pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, atypical bacteria (ie, Chlamydia",
      "pneumoniae, Mycoplasma pneumoniae, Legionella species) and viral respiratory pathogens (i.e",
      "rhinovirus and influenza)",
      "Clinical presentation",
      "•",
      "Fever,",
      "•",
      "Cough dry or productive",
      "with/without purulent sputum,",
      "•",
      "Dyspnea,",
      "•",
      "Pleuritic chest pain",
      "•",
      "Tachypnea",
      "•",
      "Crepitation/Rales heard over the",
      "involved lobe or segment",
      "•",
      "Increased tactile fremitus, bronchial",
      "breath sounds may be present if",
      "consolidation has occurred.",
      "164",
      "•",
      "Decreased",
      "tactile",
      "fremitus",
      "and",
      "dullness on chest percussion",
      "Investigations",
      "•",
      "Measure oxygen saturation use pulse oximetry or Monitor",
      "•",
      "FBC (look for increased WBC, neutrophilia),",
      "•",
      "CRP/ESR (increased in bacterial infection)",
      "•",
      "ABG (look for pH, bicarbonate),",
      "•",
      "Serology for HIV test (if Unknown)",
      "•",
      "Sputum culture and sensitivity (are indicated for inpatients and those with severe disease",
      "(ICU admission),",
      "•",
      "Blood culture (are not recommended for ambulatory patients",
      "•",
      "CHEST X-ray-PA/LATERAL (look for one or more focal pulmonary infiltrates,",
      "consolidation, tap effusion>5cm),",
      "•",
      "Bronchoscopy (Consider if immunosuppression, critically ill, fail to respond, suspected",
      "TB or PCP or inadequate",
      "•",
      "CT-CHEST Scan Or HRCT: if patient is not improving, suspicion of fungal, ILD etc.",
      "Note",
      "Do not use CT chest to diagnose pneumonia",
      "Non-pharmacological Treatment",
      "•",
      "Stop smoking if previously smoking",
      "•",
      "Vaccination when indicated, in specialized centre for patient >65yrs and below 5years",
      "Pharmacological Treatment",
      "First line treatment",
      "Table 9.3: First Line Treatment of Typical Community Acquired Pneumonia",
      "Condition",
      "Treatment",
      "Duration",
      "Mild CAP (treated on out-patient",
      "basis)",
      "(common organism S pneumonia",
      "and",
      "these",
      "patients",
      "have",
      "no",
      "comorbidities)",
      "A: erythromycin (PO) 500mg 8hourly",
      "OR",
      "B: ampicillin + cloxacillin (FDC)(PO) 500–1000mg",
      "8hourly",
      "5-7days",
      "Mild to Moderate CAP (failed to",
      "respond to Initial treatment)",
      "A: doxycycline (PO) 100 mg 12hourly (culture guided)",
      "OR",
      "B: azithromycin (PO) 500mg stat and then 250mg",
      "24hourly",
      "OR",
      "C: clarithromycin (PO) 500mg 12hourly",
      "5-7days",
      "MILD",
      "CAP",
      "in",
      "patients",
      "with",
      "comorbidities (i.e. chronic heart,",
      "lung,",
      "liver,",
      "or",
      "renal",
      "disease;",
      "diabetes",
      "mellitus;",
      "alcoholism;",
      "malignancy;",
      "asplenia;",
      "immunosuppression; prior antibiotics",
      "within 90 days",
      "B:",
      "amoxicillin",
      "+",
      "clavulanic",
      "acid",
      "(FDC)",
      "(PO)",
      "500mg/125mg 8-12hourly or   875mg/125mg 12hourly",
      "OR",
      "D: cefuroxime (PO) 500mg 12hourly",
      "AND",
      "A: doxycycline (PO) 100mg 24hourly",
      "OR",
      "C: clarithromycin (PO) 500mg 12hourly",
      "5-7 days",
      "Severe",
      "pneumonia/Aspiration",
      "pneumonia (in-patient)",
      "D: ceftriaxone + sulbactam (FDC) (IV) 1.5g 12hourly",
      "If suspicion of anaerobes or Aspiration pneumonia"
    ]
  },
  {
    "section_code": "9.2",
    "condition": "Obstructive Lung Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.2.1",
    "condition": "Asthma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.2.2",
    "condition": "Chronic Asthma in Adults",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.3",
    "condition": "Bronchitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.3.2",
    "condition": "Chronic Bronchitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.4",
    "condition": "Emphysema",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Stop smoking",
      "•",
      "Give oxygen after evaluation",
      "Pharmacological Treatment",
      "Inhaled bronchodilators relax and open the airways. They may be short-acting (albuterol,",
      "ipratropium) or long-acting (salmeterol, tiotropium,). These medicines may be available as inhalers",
      "(\"puffers\") or as a solution. A nebulizer machine aerosolizes the bronchodilator solution, which is",
      "then breathed through a tube.  For more detail refer Treatment in section 9.2 above",
      "Table 9.10: COPD Staging and recommended Therapies",
      "GOLD",
      "FEV1Stage",
      "Exacerbation",
      "Per Year",
      "Mild symptoms",
      "Mod/Severe Symptoms",
      "I: ≥80%",
      "≤2",
      "GROUP A",
      "Bronchodilator",
      "(SABA-",
      "PRN)",
      "GROUP B",
      "LAMA OR LABA",
      "II: 50-79%",
      "III: 30-49%",
      "≥2",
      "GROUP C",
      "LAMA+ LABA",
      "GROUP D",
      "LAMA or LAMA + LABA or ICS+",
      "LABA",
      "IV: 30%",
      "173"
    ]
  },
  {
    "section_code": "9.5",
    "condition": "COPD Exacerbation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6",
    "condition": "Other Respiratory Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.2",
    "condition": "Laryngeal Diphtheria",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Drug of choice",
      "A: phenoxymethylpenicillin (PO) 250mg 6hourly for 14days",
      "OR",
      "A: erythromycin (PO) 125–250mg 6hourly for 14days",
      "OR",
      "B: azithromycin (PO) 500mg 24hourly for 3days",
      "OR",
      "A: benzyl penicillin (IV) 25,000–50,000units/kg to a max. of 1.2MU 12hourly until the",
      "patient can take oral medicine",
      "AND",
      "A: diphtheria antitoxin (IM or slow IV) dose depends upon the site and severity of infection:",
      "•",
      "First give a test dose of 0.1ml of 1 in 10 dilution of antitoxin in 0.9% Sodium Chloride",
      "intradermal to detect hypersensitivity",
      "•",
      "It should be given immediately because delay can lead to increased mortality",
      "•",
      "The dose should be administered intravenously over 60minutes in order to inactivate toxin",
      "rapidly",
      "•",
      "20,000–40,000 units for pharyngeal/laryngeal disease of <48 hours’ duration,",
      "•",
      "40,000–60,000 units for nasopharyngeal disease",
      "•",
      "80,000–120,000 units for >3days of illness or diffuse neck swelling \"bull-neck\"",
      "Note",
      "Tracheostomy may be required for airway obstruction"
    ]
  },
  {
    "section_code": "9.6.3",
    "condition": "Whooping Cough",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.4",
    "condition": "Bronchiectasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.5",
    "condition": "Lung Abscess",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.6",
    "condition": "Aspergilosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.7",
    "condition": "Pneumocystis Pneumonia (PCP)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.8",
    "condition": "Silicosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.9",
    "condition": "Coal worker’s pneumoconiosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.10",
    "condition": "Sarcoidosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.11",
    "condition": "Obstructive Sleep Apnea Syndrome (OSA)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.12",
    "condition": "Cor Pulmonale",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.13",
    "condition": "Pleural Effusion",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "9.6.14",
    "condition": "Respiratory Failure",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1",
    "condition": "Infections of Gastrointestinal Tract",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.2",
    "condition": "Amoebic Liver Abscess",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.4",
    "condition": "Ascariasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.5",
    "condition": "Ancylostomiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.6",
    "condition": "Strongyloidiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.7",
    "condition": "Taeniasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.8",
    "condition": "Echinococcosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.9",
    "condition": "Schistosomiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.10",
    "condition": "Typhoid and Paratyphoid",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.11",
    "condition": "Shigellosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.1.12",
    "condition": "Cholera",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.2.1",
    "condition": "Peptic Ulcer Disease",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.2.2",
    "condition": "Ulcer Related Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.2.3",
    "condition": "Gastrointestinal (GI) Bleeding",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3",
    "condition": "Diseases of the Intestine",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.2",
    "condition": "Pseudomembranous Colitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.3",
    "condition": "Radiation Proctitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.4",
    "condition": "Irritable Bowel Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.5",
    "condition": "Diverticulosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.6",
    "condition": "Diverticulitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.7",
    "condition": "Polyps and Adenomas",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.8",
    "condition": "Hemorrhoids",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.9",
    "condition": "Anal Fissures",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.10",
    "condition": "Fistula in Ano",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.3.11",
    "condition": "Appendicitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4",
    "condition": "Pancreatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.1",
    "condition": "Acute Pancreatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.2",
    "condition": "Chronic Pancreatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4",
    "condition": "Disorders of The Liver and Biliary Tract",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.2",
    "condition": "Portal Hypertension",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "10.4.3",
    "condition": "Biliary Tract Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.1",
    "condition": "Bleeding in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.1.1",
    "condition": "Abortion",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2",
    "condition": "Ectopic Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2.1",
    "condition": "Un-ruptured Ectopic Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.2.2",
    "condition": "Ruptured Ectopic Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.3",
    "condition": "Antepartum Hemorrhage",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.3.1",
    "condition": "Placenta Praevia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.4",
    "condition": "Obstructed Labour",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.5",
    "condition": "Postpartum Hemorrhage (PPH)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.6",
    "condition": "Prelabour Rupture of Membranes (PROM)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7",
    "condition": "Antenatal Care",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.2",
    "condition": "Hypertensive Disorders in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.3",
    "condition": "Pre-eclampsia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.4",
    "condition": "HELLP syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.5",
    "condition": "Eclampsia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.6",
    "condition": "Antiphospholipid Syndrome (APS) in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.7",
    "condition": "Deep Vein Thrombosis in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.8",
    "condition": "Pulmonary Embolism in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.9",
    "condition": "Vomiting in Pregnancy and Hyperemesis Gravidarum",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.10",
    "condition": "Heartburn in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.11",
    "condition": "Other Medical Disorders in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.12",
    "condition": "Stimulation of Labour and Myometrial Relaxation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.7.13",
    "condition": "Rhesus Incompatibility",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8",
    "condition": "Postpartum Care",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.2",
    "condition": "Puerperal Sepsis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.3",
    "condition": "Abnormal Uterine Bleeding (AUB)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.4",
    "condition": "Dysmenorrhea",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.5",
    "condition": "Endometriosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.9",
    "condition": "Contraception",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.9.2",
    "condition": "Long-term Contraceptive methods",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.9.3",
    "condition": "Permanent (surgical) Contraceptive Methods",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.8.4",
    "condition": "Infertility",
    "definition": "",
    "investigations": [
      "Not every fertility test will be done for every case.",
      "WOMEN: For women, fertility testing may include basic gynaecologic examination",
      "•",
      "VDRL tests",
      "•",
      "Urine routine and microscopic",
      "•",
      "Cervical mucus examination",
      "•",
      "Abdominal pelvic/Transvaginal USS",
      "•",
      "HSG (hysterosalpingogram)for tubal patency",
      "•",
      "Hysteroscopy-",
      "•",
      "Diagnostic laparoscopy- This test is only done when symptoms point to possible",
      "endometriosis, as part of treatment for blocked fallopian tubes, or in some cases of",
      "unexplained infertility.",
      "•",
      "Hormonal profile- FSH, LH, TSH, AMH, T3 & T4, Testosterone, prolactin, estradiol and",
      "progesterone.",
      "243",
      "MEN: Perform the following",
      "•",
      "Semen analysis",
      "•",
      "VDRL tests",
      "•",
      "Hormonal profile-FSH, Testosterone, but sometimes also LH, estradiol, or prolactin",
      "Treatment will depend on the underlying cause",
      "Non-pharmacological Treatment",
      "•",
      "Weight reduction in obese clients.",
      "•",
      "Educate the couple on the importance of having sexual intercourse during the fertile",
      "window",
      "•",
      "Try to avoid smoking/excessive drinking",
      "Pharmacological Treatment",
      "Ovulation stimulation;",
      "C: clomiphene citrate (PO) 50mg 24hourly for 5days from the 2nd–5th day of",
      "menstruation. (maximum 6 cycles)",
      "Polycystic Ovarian Syndrome (PCOS)",
      "A: metformin (PO) 500mg 8hourly is used for PCOS treatment, alone or along with fertility",
      "drugs",
      "Hyperprolactinemia",
      "C: bromocriptine (PO) 2.5–5mg 24hourly until the prolactin level is within the normal range",
      "OR",
      "S: cabergoline (PO) 0.25–0.5mg once or twice weekly initially then the dose is gradually",
      "increased monthly until prolactin levels normalize. Doses of less than 3mg per week are",
      "usually enough to achieve this goal"
    ],
    "treatment": []
  },
  {
    "section_code": "12.1",
    "condition": "STIs/RTIs Management Approaches",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.2",
    "condition": "Urethral Discharge Syndrome (UDS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.3",
    "condition": "Vaginal Discharge Syndrome (VDS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.4",
    "condition": "Lower Abdominal Pain Syndrome or Pelvic Inflammatory Disease (PID)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.5",
    "condition": "Painful Scrotal Swelling (PSS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.6",
    "condition": "Ano-rectal Syndrome (ARS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.7",
    "condition": "Oropharyngeal Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.8",
    "condition": "Genital Ulcer Disease (GUD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.9",
    "condition": "Neonatal Conjunctivitis (Ophthalmia Neonatorum)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.10",
    "condition": "Inguinal Bubo (IB)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.8",
    "condition": "Management of Other Common STI Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1",
    "condition": "Bacterial Skin Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.1",
    "condition": "Impetigo",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.2",
    "condition": "Folliculitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.3",
    "condition": "Abscess",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.4",
    "condition": "Erysipelas and Cellulitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.1.5",
    "condition": "Paronychia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2",
    "condition": "Fungal Skin Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.2",
    "condition": "Tinea Capitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.3",
    "condition": "Pityriasis Versicolor",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.4",
    "condition": "Tinea Pedis (Athlete’s Foot) and Tinea Cruris",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.5",
    "condition": "Candidiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.6",
    "condition": "Onychomycosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.7",
    "condition": "Chromoblastomycosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.2.8",
    "condition": "Mycetoma (Madura Foot)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.3",
    "condition": "Parasitic Infestations",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4",
    "condition": "Viral Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.2",
    "condition": "Chickenpox",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.3",
    "condition": "Herpes Zoster (Shingles)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.4",
    "condition": "Post-herpetic Neuralgia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.4.5",
    "condition": "Molluscum Contagiosum",
    "definition": "",
    "investigations": [],
    "treatment": [
      "A: benzoyl peroxide 24hourly for 4weeks",
      "OR",
      "S: tretinoin cream (topical) 2.5 % 24hourly for 4weeks",
      "271",
      "Surgical treatment",
      "C: Cryotherapy",
      "D: Curatage"
    ]
  },
  {
    "section_code": "13.4.6",
    "condition": "Viral Warts",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5",
    "condition": "Eczema (Dermatitis) Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5.2",
    "condition": "Atopic Eczema",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.5.3",
    "condition": "Seborrheic Dermatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.6",
    "condition": "Anaphylaxis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.7",
    "condition": "Papulosquamous Disorder",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.7.3",
    "condition": "Acne",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.8",
    "condition": "Drug Reactions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.8.1",
    "condition": "Fixed Drug Eruption (FDE)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.8.3",
    "condition": "Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.10",
    "condition": "Pellagra",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.11",
    "condition": "Vitiligo",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.12",
    "condition": "Pruritic Papular Eruption (PPE)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.13",
    "condition": "Oculo-cutaneous Albinism and Xeroderma Pigmentosum",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.14",
    "condition": "Urticaria and Angioedema",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.15",
    "condition": "Connective Tissue Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.17",
    "condition": "Keloids",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.18",
    "condition": "Folliculitis Decalvans",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.19",
    "condition": "Infantile Haemangioma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.20",
    "condition": "Cysts",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "13.21",
    "condition": "Skin Lightening",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1",
    "condition": "Major Blinding Eye Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.1",
    "condition": "Cataract",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.2",
    "condition": "Glaucoma",
    "definition": "",
    "investigations": [
      "•",
      "Visual Acuity",
      "•",
      "Slit Lamp bimicroscopy",
      "•",
      "Fundoscopy",
      "•",
      "Tonometry",
      "•",
      "Gonioscopy",
      "•",
      "Refraction",
      "•",
      "Visual Field Analysis",
      "•",
      "Fundus Photography",
      "•",
      "Pachymetry test",
      "•",
      "Optical Coherent Tomography",
      "Pharmacological Treatment",
      "This is initiated after a diagnosis is reached by an ophthalmologist, refill of some medicines can be",
      "done by Assistant Medical Officers in ophthalmology but with regular reviews at a health facility with",
      "eye specialist. Medical treatment should be lifelong unless there are conditions necessitating other",
      "interventions",
      "C: timolol 0.25% or 0.5%, one drop in the affected eye, instill 12hourly.",
      "OR",
      "287",
      "D: betaxolol 0.25% or 0.5%, one drop in the affected eye, instill 12hourly. Use lower",
      "strength in mild disease and those at risk of complications.",
      "In patients who comply to treatment and there is no good response",
      "ADD",
      "D: latanoprost 0.005% one drop, 2hourly in the affected eye.",
      "OR",
      "D: prostamide bimatoprost 0.03%, one drop, 24hourly in the affected eye.",
      "•",
      "These may be used as first-line in patients with contraindication of beta-blockers.",
      "•",
      "They can be used as a second-line drug in patients on beta-blockers if the target IOP",
      "reduction has not been reached.",
      "In patients who are intolerant to prostaglandin analogue or are not responding give:",
      "D: brimonidine tartrate 0.15–0.2%, one drop, 12hourly, in the affected eye.",
      "OR",
      "S: dorzolamide 20mg/mL, one drop, 8hourly in the affected eye",
      "Failure to respond give:",
      "C: pilocarpine hydrochloride 2% or 4%, instill one drop in the affected eye 6 hourly.",
      "Note",
      "Pilocarpine causes long-standing pupil constriction so it should not be used unless a patient is",
      "prepared for glaucoma",
      "surgery or as an alternative topical treatment for patients who are contraindicated for Timolol use.",
      "Consult a specialist",
      "before using it.",
      "In severe cases or while waiting for surgery, use:",
      "C: acetazolamide (PO) 250mg 6hourly",
      "Note",
      "•",
      "β-blockers are contraindicated to people who are known to have overt asthma as this",
      "group of medication may cause an acute asthmatic attack within a short time following",
      "instillation into the eye",
      "•",
      "Brimonidine is contraindicated in children below 12years",
      "Laser Treatment",
      "•",
      "It may be indicated in addition to or instead of eye drops or surgery.",
      "•",
      "Laser trabeculoplasty (Argon Laser Trabeculoplasty, Selective Laser Trabeculoplasty) or",
      "cyclophotocoagulation are different options among others",
      "Surgical Treatment",
      "It is done in all patients with poor compliance and when medical treatment is not useful. There are",
      "different surgical techniques depending on the age of the patients, patients’ response to surgical",
      "treatment, surgeons’ surgical skills and availability of equipment. It is recommended that all",
      "surgeries are done by Ophthalmologists after thorough assessment of the patients.",
      "14.1.2.2 Angle Closure Glaucoma",
      "This is also known as Congestive glaucoma and commonly affect people aged 40 years and above.",
      "It affects more females than males.",
      "Clinical Presentation",
      "•",
      "Acute sudden onset of painful red",
      "eye in the affected eye",
      "•",
      "Severe headache and cloudiness",
      "of the cornea",
      "•",
      "Shallow anterior chamber",
      "•",
      "Fixed and semi-dilated pupil",
      "288",
      "•",
      "Severe",
      "elevated",
      "intraocular",
      "pressure.",
      "•",
      "There is usually dramatic visual",
      "impairment and vomiting may be",
      "present",
      "•",
      "It may be asymptomatic if IOP",
      "raises slowly"
    ],
    "treatment": []
  },
  {
    "section_code": "14.1.3",
    "condition": "Trachoma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.4",
    "condition": "Diseases of the Retina",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.5",
    "condition": "Refractive Errors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.1.6",
    "condition": "Low Vision",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2",
    "condition": "Painful Red Eyes",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.1",
    "condition": "Ocular Trauma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.2",
    "condition": "Herpes Simplex Keratitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.3",
    "condition": "Corneal Ulcer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.4",
    "condition": "Uveitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.2.5",
    "condition": "Conjunctivitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.3",
    "condition": "Structural Abnormalities of the Eye",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.4",
    "condition": "Ocular Oncology",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.4.2",
    "condition": "Squamous Cell Carcinoma of Conjunctiva",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.5",
    "condition": "Dry Eye",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.6",
    "condition": "Herpes Zoster Ophthalmicus",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.7",
    "condition": "Endophthalmitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.8",
    "condition": "Retinitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.9",
    "condition": "Orbital Cellulitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.10",
    "condition": "Visual Problems",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "14.11",
    "condition": "Onchocerciasis (River Blindness)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1",
    "condition": "Ear Condition",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.2",
    "condition": "Diffusewer Otitis Externa (Swimmer’s ear)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.3",
    "condition": "Necrotizing Otitis Externa",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.4",
    "condition": "Herpes Zoster Oticus (Ramsay Hunt syndrome)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.1.5",
    "condition": "Pre-auricular Sinus Tract Infection",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2",
    "condition": "Trauma of the Pinna",
    "definition": "",
    "investigations": [],
    "treatment": [
      "B: ampicilin+cloxacillin (FDC) (PO) 500mg 8hourly for 7-10days"
    ]
  },
  {
    "section_code": "15.2.2",
    "condition": "Laceration of the Pinna",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2.3",
    "condition": "Ear Keloid",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.2.4",
    "condition": "Cerumen Impaction",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Remove using cerumen hook, syringing or suctioning under direct vision",
      "Note",
      "Patient should be educated on cleansing mechanism of the ear and not to use cotton bud."
    ]
  },
  {
    "section_code": "15.2.5",
    "condition": "Foreign Body in the Ear",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Restrain the child",
      "•",
      "Remove using a cerumen hook under",
      "direct vision (if the child cannot be",
      "restrained, sedation is advised)",
      "•",
      "An insect should be killed (by soaking",
      "the ear canal with normal saline or spirit)",
      "before removal",
      "Note",
      "Do not attempt to remove ear foreign body if you don’t have proper instruments and expertise."
    ]
  },
  {
    "section_code": "15.2.6",
    "condition": "Traumatic Tympanic Membrane/ Ear Drum Perforation.",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.3",
    "condition": "Otitis Media (Acute or Chronic)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.3.1",
    "condition": "Acute Otitis Media",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Acute otitis media should be treated with analgesics, antibiotics and/or paracentesis/",
      "(Myringotomy) to reduce pain and to obtain pus for culture and sensitivity)",
      "Pharmacological Treatment:",
      "B: amoxicillin+clavulanic acid (PO) 375–625mg 12hourly for 10days",
      "OR",
      "A: azithromycin (PO) 500mg 24 hourly for 5days (for patients who are allergic to penicillin) For",
      "Children",
      "A: azithromycin (PO) 10mg/kg 24hourly for 5days",
      "OR",
      "B: ceftriaxone (IV) 1 to 2 g    12hourly for 10days.",
      "For Children:",
      "B:  ceftriaxone (IV) 50 to 100mg/kg 24hourly for 10days",
      "OR",
      "C: clarithromycin (PO) 500mg 12hourly for 10-14days.",
      "ForChildren ≥ 6 months:",
      "C: clarithromycin (PO) 15mg/kg/day in 2divided doses for 10-14days",
      "OR",
      "S: cefixime (PO) 400mg 24hourly for 10-4days",
      "322",
      "For Children ≥ 6 months to 12 years (weight below 45kg):",
      "S: cefixime (PO) 8mg/kg 24hourly for 10-14days",
      "AND",
      "A: paracetamol (PO) 500mg to 1g 4-8hourly for 3days.",
      "For Children ≤ 10kg:",
      "A: paracetamol (PO) 10mg/kg 4-8hourly for 3days",
      "For Children >10kg:",
      "A: paracetamol (PO) 15mg/kg 4-8 hourly for 3days.",
      "OR",
      "A: ibuprofen (PO) 200mg to 400mg 4-8hourly as needed.",
      "For Children ≥ 6 months:",
      "A: ibuprofen (PO) 5mg to 10mg/kg 4-8hourly as needed",
      "OR",
      "C: diclofenac+ paracetamol (PO) 50mg diclofenac and 500mg paracetamol 4-8hourly as",
      "needed"
    ]
  },
  {
    "section_code": "15.3.2",
    "condition": "Chronic Suppurative Otitis Media",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Keep ear dry/avoid water into the ear",
      "•",
      "Aural toilet – ear suctioning under direct vision(otomicroscopy/endoscopy), removal of debris",
      "•",
      "Ear wicking regularly, with a dry cotton wick at home",
      "Pharmacological Treatment",
      "C: ciprofloxacin ear drops, three drops12hourly for 14days",
      "A: hydrogen peroxide 3% ear drops: 2 to 4 drops each ear 6-8hourly for 14days",
      "OR",
      "A: boric acid ear drops: 2-4 drops each ear 6-8hourly for 14days",
      "OR",
      "D: ofloxacin ear drops: 2 to 4 drops each ear 6-8hourly for 14days",
      "AND",
      "A: ciprofloxacin (PO) 500mg 12hourly for 10days",
      "ForChildren:",
      "A: ciprofloxacin (PO) 10–20mg/kg 12hourly for 10days",
      "Surgical management",
      "•",
      "Mastoidectomy",
      "•",
      "Endoscopic tympanoplasty",
      "•",
      "Tympano-mastoidectomy",
      "•",
      "Ossiculoplasty",
      "323",
      "Note",
      "Treatment of shorter than 10 days will result into treatment failure",
      "Avoid ototoxic drugs(gentamycin , neomycin and quinine) if there is TM perforation"
    ]
  },
  {
    "section_code": "15.3.3",
    "condition": "Mastoditis with Sub-Periosteal Abscess",
    "definition": "",
    "investigations": [],
    "treatment": [
      "C: ciprofloxacin ear drops, 3drops, 12hourly for 14days",
      "AND",
      "A: ciprofloxacin (PO) 500mg 12hourly for 10days; Children 10–20mg/kg 12hourly for",
      "10days",
      "Investigations",
      "•",
      "Culture &sensitivity",
      "•",
      "CT SCAN-Temporal Bone",
      "Surgical management",
      "•",
      "Incision and drainage",
      "•",
      "Mastoidectomy/Drainage",
      "mastoidectomy",
      "•",
      "Tympano-mastoidectomy",
      "•",
      "Ossiculoplasty",
      "Note",
      "Treatment shorter than 10days will result into treatment failure"
    ]
  },
  {
    "section_code": "15.3.4",
    "condition": "Otitis Media with Effusion",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4",
    "condition": "Hearing Loss",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.1",
    "condition": "Sensorineural Hearing Loss (SNHL)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.2",
    "condition": "Sudden Sensorineural Hearing Loss",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.3",
    "condition": "Otosclerosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.4",
    "condition": "Peripheral Vertigo (Meniere’s disease and Benign Paroxysmal Positional",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.5",
    "condition": "Vestibular Neuritis /Vestibular Neuronitis and Labyrinthitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.6",
    "condition": "Vestibular Migraine",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.7",
    "condition": "Tinnitus",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.8",
    "condition": "Glomus Tumours",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.4.9",
    "condition": "Vestibular Schwannomas",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5",
    "condition": "Nose/Paranasal Sinuses Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5.2",
    "condition": "Acute Non-Allergic Rhinitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.5.3",
    "condition": "Allergic Rhinitis",
    "definition": "",
    "investigations": [],
    "treatment": [
      "A: ephedrine (0.5% and 1%)nasal drop, Adults and children above 12years: Instill 1 to",
      "2drops in each nostril, not more than 4 times a day for 3-5days",
      "OR",
      "C: oxymetazoline (0.5%) nasal drops/spray, Adults and children above 6 years: Instill 2- 3",
      "drops or sprays in each nostril every after 12 hours for 3-5days",
      "AND",
      "D: fluticasone propionate (50mcg/spray) nasal spray, Adults and adolescents more than",
      "12years: 2sprays in each nostril 24 hourly as needed. children 4-11years: 1spray in each",
      "nostril 24hourly as needed",
      "OR",
      "S: mometasone nasal spray, Adults and adolescents from 12years: 1 sprays in each",
      "nostril 24 hourly as needed. children 6 to 11 years: 1 spray in each nostril 24 hourly as",
      "needed.",
      "AND",
      "A: prednisolone (PO): 60mg 24hourly for 5days then taper down to 50mg 24 hourly for",
      "next 5days. Children: 1mg/kg 24hourly for 5days then taper down by half for the next",
      "5days.",
      "AND",
      "C: loratadine (PO), Adults: 10mg 24hourly for 30days. Children 2-6years: 5mg 24hourly for",
      "14days. Children above 6 years: 10mg 24 hourly for 14 days",
      "OR",
      "S: desloratadine (PO)Adults: 5mg 24hourly for 30days. Children 2-5 years: 1.25mg",
      "24hourly for 14days. Children 6 to 12 years: 2.5mg 24hourly for 30days",
      "AND",
      "S: montelukast, Adults: 10mg 24hourly for 30days.Children 1-15 years: 5mg 24hourly for",
      "14days"
    ]
  },
  {
    "section_code": "15.6",
    "condition": "Granulomatous Diseases of the Nose",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.2",
    "condition": "Tuberculosis of the Nose",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.3",
    "condition": "Syphilis of the Nose",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.6.4",
    "condition": "Rhinosporiodiosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7",
    "condition": "Other Conditions of the Nose",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.3",
    "condition": "Nasal Turbinate Hypertrophy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.4",
    "condition": "Nasal Bone Fracture",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.5",
    "condition": "Nasal Septal Deviation (Non-Traumatic)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.6",
    "condition": "Adenoid Hypertrophy",
    "definition": "",
    "investigations": [
      "Nasopharynx lateral view X-ray.",
      "Pharmacological Treatment:",
      "A: cetirizine (PO) 10mg nocte for 2weeks. Children: 5mg nocte for 2weeks",
      "AND",
      "A: 0.9% sodium chloride nasal spray/drops 4hourly for 2weeks",
      "AND",
      "B: azithromycin (PO) 500mg 24hourly for 3days. Children: 10mg/kg 24 hourly for 3days",
      "OR",
      "B: amoxicillin+clavulanic acid (PO) (FDC) Adults: 625mg (500mg amoxicillin+125mg",
      "Clavulanic acid) 8hourly for 7days"
    ],
    "treatment": [
      "A: cetirizine (PO) 10mg nocte for 2weeks. Children: 5mg nocte for 2weeks",
      "AND",
      "A: 0.9% sodium chloride nasal spray/drops 4hourly for 2weeks",
      "AND",
      "B: azithromycin (PO) 500mg 24hourly for 3days. Children: 10mg/kg 24 hourly for 3days",
      "OR",
      "B: amoxicillin+clavulanic acid (PO) (FDC) Adults: 625mg (500mg amoxicillin+125mg",
      "Clavulanic acid) 8hourly for 7days"
    ]
  },
  {
    "section_code": "15.7.7",
    "condition": "Acute Rhinosinusitis",
    "definition": "",
    "investigations": [],
    "treatment": [
      "B: azithromycin (PO) 500mg 24hourly for 3days. Children: 10mg/kg 24hourly for 3days",
      "OR",
      "B: amoxicillin+clavulanic acid (PO) 625mg 8hourly for 7days Children: 375mg 12hourly for",
      "7days;",
      "OR",
      "333",
      "C: clarithromycin (PO), 500mg 12hourly for 7-14days. Children ≥ 6 months: 15mg/kg/day",
      "in 2divided doses for 7-14days",
      "OR",
      "B: ceftriaxone (IV) Adults: 1-2 g12hourly for 7 days. Children: 50 to 100mg/kg once for",
      "7days",
      "OR",
      "S: cefixime (PO) Adults: 400mg 24hourly for 7-14 days. Children ≥ 6 months to 12years",
      "(weight below 45kg): 8mg/kg 24hourly for 7-14days",
      "AND (for fungal rhinosinusitis)",
      "D: itraconazole (PO) Adults: 200mg 24hourly for 30days. Children: 50-100mg/kg once for",
      "7days",
      "OR",
      "S: amphotericin B (IV) Adults: Test dose of 1mg IV infused over 20-30minutes. Loading",
      "dose of 0.25-0.5mg/kg IV infused over 2 to 6 hourly. Maintenance dose of 0.25-1mg/kg",
      "24hourly for 3-6weeks for children: Test dose of 0.1mg/kg not to exceed 1mg:  infused",
      "over 20-60minutes Loading dose of 0.25mg/kg infused over 2-6hours. Maintenance dose",
      "of 0.25/kg 24hourly to ensure a total dose of 30-40mg/kg is given over 3-6weeks",
      "AND",
      "B: ephedrine (0.5% and 1%) nasal drop, Adults and children above 12years: Instill 1 to",
      "2drops in each nostril, not more than 4 times a day for 3 to 5days",
      "OR",
      "S: xylometazoline (0.05% and 0.1%) nasal drops/spray, Adults and children above 6years:",
      "Instill 2 to 3drops in each nostril 8hourly for 3 to 5days or1 to 2sprays in each nostril",
      "8hourly for 3 to 5days",
      "OR",
      "D: fluticasone propionate (50mcg/spray) nasal spray, Adults and adolescents more than",
      "12years: 2sprays in each nostril 24hourly as needed. Children 4-11years: 1spray in each",
      "nostril 24hourly as needed",
      "OR",
      "S: mometasone nasal spray, Adults and adolescents from 12years: 1sprays in each nostril",
      "24hourly as needed. Children 6-11years: 1spray in each nostril 24hourly as needed.",
      "AND",
      "A: paracetamol (PO) Adults: 500mg to 1g 4-8hourly as needed. Children ≤ 10kg: 10mg/kg",
      "4-8hourly as needed. Children >10kg: 15mg/kg 4-8hourly as needed",
      "OR",
      "A: diclofenac (IM) Adults: 75mg 8hourly as needed",
      "OR",
      "C: diclofenac (PO) Adults: 50mg 4-8 hourly as needed",
      "OR",
      "C: ibuprofen (PO) Adults: 200-400mg 4-8 hourly as needed. Children ≥ 6 months: 5-",
      "10mg/kg 4-8hourly as needed",
      "Non-pharmacological management",
      "•",
      "Saline nasal wash",
      "•",
      "Steaming with or without Vicks"
    ]
  },
  {
    "section_code": "15.7.8",
    "condition": "Chronic Rhinosinusitis",
    "definition": "",
    "investigations": [],
    "treatment": [
      "as for acute sinusitis BUT should be for 4-6 weeks",
      "Surgical Management-Surgery if associated with complications eg obital/periobital abscess, pottys",
      "puffy tumour, Brain abscess and nasal polyposis etc and Failure of disease resolution after",
      "adequate medical treatment.",
      "Frontal Trephination",
      "OR",
      "Caldwel Luc operation",
      "OR",
      "Open ethimoidectomy",
      "OR",
      "Functional Endoscopic Sinus Surgery (FESS)"
    ]
  },
  {
    "section_code": "15.7.9",
    "condition": "Nasal Polyposis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.7.10",
    "condition": "Nose Bleeding (Epistaxis)",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Restrain the child before removal using a cerumen hook, if the child cannot be restrained",
      "sedation is advised",
      "Note",
      "A unilateral foul smelling nasal discharge in a child is due to a foreign body until proven otherwise"
    ]
  },
  {
    "section_code": "15.8",
    "condition": "Throat Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.2",
    "condition": "Laryngitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.3",
    "condition": "Acute Laryngitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.1",
    "condition": "ml",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.15",
    "condition": "ml",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.2",
    "condition": "ml",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.4",
    "condition": "Chronic Laryngitis",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Voice rest",
      "•",
      "Stop smoking",
      "•",
      "Rehydration",
      "•",
      "Refer to specialist for Rigid",
      "laryngoscopy (Endoscopy) OR",
      "Fiber optic Nasolaryngoscopy"
    ]
  },
  {
    "section_code": "15.8.5",
    "condition": "Acute Epiglottitis (AE)",
    "definition": "",
    "investigations": [
      "Plain X-ray of the neck, lateral view characteristically presents with a positive thumb",
      "sign (edematous epiglottis).",
      "Non-pharmacological Treatment:",
      "•",
      "Immediate hospitalization, preferably in the ICU",
      "•"
    ],
    "treatment": [
      "•",
      "Immediate hospitalization, preferably in the ICU",
      "•"
    ]
  },
  {
    "section_code": "15.8.6",
    "condition": "Non-infectious Chronic Laryngitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.7",
    "condition": "Recurrent Respiratory Papillomatosis (Laryngeal Papillomas)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.9",
    "condition": "Subglottic Hemangioma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.9",
    "condition": "Laryngomalacia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.10",
    "condition": "Vocal Cords Paralysis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.11",
    "condition": "Infection of Thyroglossal Duct Cyst, Dermoid Cyst, Branchial Cleft",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.12",
    "condition": "Deep Neck Spaces Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.8.13",
    "condition": "Peritonsillar Abscess (Quincy)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9",
    "condition": "ENT Neoplasms",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.2",
    "condition": "Salivary Gland Tumors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.3",
    "condition": "Parapharyngeal Tumours",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.4",
    "condition": "Cancer of the Larynx",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.5",
    "condition": "Sino-Nasal Malignancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.6",
    "condition": "Naso-Pharyngeal Malignancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.7",
    "condition": "Oropharyngeal Malignancy",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Refer Malignancy chapter."
    ]
  },
  {
    "section_code": "15.9.8",
    "condition": "Hypo-Pharyngeal Malignancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "15.9.9",
    "condition": "Metastatic Lymphadenopathy and Neck Masses",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1",
    "condition": "Periodontal Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1.2",
    "condition": "Periodontitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1.3",
    "condition": "Acute Necrotizing Ulcerative Gingivitis (ANUG)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.1.4",
    "condition": "Stomatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.2",
    "condition": "Dental Caries",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3",
    "condition": "Odontogenic and Non-Odontogenic Orofacial Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.2",
    "condition": "Dental Abscess (Odontogenic Abscess)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.3",
    "condition": "Ludwig’s Angina",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.4",
    "condition": "Pericoronitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.3.5",
    "condition": "Osteomyelitis of the Jaw",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.4.1",
    "condition": "Oral Candidiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.5",
    "condition": "Viral Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.6",
    "condition": "Aphthous Ulceration",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7",
    "condition": "Post Extraction Complications",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7.2",
    "condition": "Infected Socket",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7.3",
    "condition": "Dry Socket",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.7.4",
    "condition": "Oro-Antral Communication",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.8",
    "condition": "Tooth Sensitivities",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.9",
    "condition": "Tooth Eruption, Shedding and Edentulousness",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.9.2",
    "condition": "Shedding of Deciduous Teeth",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.9.3",
    "condition": "Edentulousness",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.10",
    "condition": "Malocclusions",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Preventive orthodontics",
      "It includes parent counselling, caries control, space maintenance, managing exfoliation of deciduous",
      "teeth, release of abnormal frenal attachments, treatment of blocked permanent first molars,",
      "management of abnormal oral musculature and related habits.",
      "•",
      "Interception orthodontics",
      "o",
      "Correction of anterior or posterior cross bite, relieving crowding of the permanent",
      "dentition, Space closure, treatment of anterior open bite, Deep bite, reverse overjet,",
      "proclination of the upper labial segment and oral habits management by patient",
      "education and monitoring or removable and fixed habit breaker",
      "o",
      "For skeletal malocclusion: Use of extra oral appliances like reverse pull headgear",
      "combined with an RME, high pull head gear and chin cups or functional appliances",
      "are indicated for skeletal malocclusion in growing patients",
      "•",
      "Definitive Orthodontic",
      "Alignment of teeth in patient with dental alveolar malocclusion by using removable, clear aligner or",
      "fixed appliances. Simple removable appliances are very useful in our local settings especially for",
      "mild to moderate malocclusion in teenagers and include retainers or space maintainers."
    ]
  },
  {
    "section_code": "16.11",
    "condition": "Management of Maxillofacial Trauma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.11.2",
    "condition": "Facial Bones Injuries",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12",
    "condition": "Tumours and Tumour-Like Conditions of Oral Cavity and Facial Region",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.2",
    "condition": "Non Odontogenic Benign Tumours",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.3",
    "condition": "Benign Soft Tissues Non-Odontogenic Tumours",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.12.4",
    "condition": "Malignant Soft and Bone",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14",
    "condition": "Temporal Mandibular Disorder and Chronic Orofacial Pain",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14.1",
    "condition": "Chronic Orofacial Pain other than Temporomandibular Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14.2",
    "condition": "Temporomandibular Disorders (TMDs)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "16.14.3",
    "condition": "Osteoarthritis and Rheumatoid arthritis of TMJ",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1",
    "condition": "Infections",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.1.2",
    "condition": "Septic Arthritis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2",
    "condition": "Inflammatory Conditions",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.1",
    "condition": "Rheumatoid Arthritis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.4",
    "condition": "Osteoarthritis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.5",
    "condition": "Heterotopic Ossification",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.6",
    "condition": "Tendinopathies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.2.7",
    "condition": "Plantar Fasciitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.3.1",
    "condition": "Osteoporosis and Brittle Bone Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.5",
    "condition": "Affection of the Brain and Spine",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.5.3",
    "condition": "Pyogenic Spondylodiscitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.8.1",
    "condition": "Rickets",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "17.8.2",
    "condition": "Physiological Bowing/Knocked Knees",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.1",
    "condition": "Diabetes Mellitus",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "11.0",
    "condition": "mmol/l are considered overt diabetes rather than GDM",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.2",
    "condition": "Management of Diabetes During Religious Fasting",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.3",
    "condition": "Hyperglycaemia in Pregnancy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.4",
    "condition": "Diabetes and HIV",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.5",
    "condition": "Diabetes and Tuberculosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.6",
    "condition": "Hypoglycaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.7",
    "condition": "Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic States",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.8",
    "condition": "Diabetes and Cardiovascular Diseases",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.9",
    "condition": "Diabetic Peripheral Neuropathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.10",
    "condition": "Diabetic Nephropathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.11",
    "condition": "Diabetic Retinopathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12",
    "condition": "Thyroid Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.1",
    "condition": "Hypothyroidism",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.2",
    "condition": "Hyperthyroidism",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.3",
    "condition": "Toxic Multinodular Goitre or Thyroid Antibody Positive",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.4",
    "condition": "Grave’s Hyperthyroidism",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.35",
    "condition": "mL) Lugol’s solution (8 mg iodide/drop) or 1–2 drops (0.05–0.1 mL) saturated solution of",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.12.5",
    "condition": "Thyroid Storm (Crisis)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.13",
    "condition": "Cushing's Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.14",
    "condition": "Prolactinoma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.15",
    "condition": "Diabetic Insipidus (DI)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.16",
    "condition": "Pheochromocytoma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.17",
    "condition": "Disorder of Sexual Development (DSD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.8",
    "condition": "Obesity in Adults",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "19.19",
    "condition": "Physical Activity",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.1",
    "condition": "Prevention of Atherosclerotic Ischaemic Heart Disease and Stroke",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Forspecific pharmacological treatment for hypertension, diabetes,",
      "dyslipidemia refer specific sections, respectively."
    ]
  },
  {
    "section_code": "20.2",
    "condition": "Management of Dyslipidemias",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.3",
    "condition": "Chronic Stable Coronary Artery Disease (CSCAD) / ISCHAEMIC Heart",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.4",
    "condition": "Acute Coronary Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.4.2",
    "condition": "Non-ST Elevation Myocardial Infarction (NSTEMI)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.4.3",
    "condition": "ST Elevation Myocardial Infarction (STEMI)",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Supportive therapy",
      "•",
      "Consider cardio-pulmonary resuscitation if necessary, before transfer (cardiac arrest–",
      "cardiopulmonary resuscitation).",
      "•",
      "Oxygen 40% via facemask, if saturation < 92% or if in distress",
      "•",
      "See section 20.4.2 above on supportive therapy for NSTEMI",
      "Adjunctive therapy",
      "Control cardiac pain",
      "C: glyceryl trinitrate sub-lingual/ spray 0.5mg (make sure patient hasn’t taken",
      "phosphodiesterase-5 inhibitor).",
      "For persistent pain and if oral therapy is insufficient",
      "S: glyceryl Trinitrate (IV) 1–2 µg/kg/min titrated with chest pain over 8–24 hours.",
      "OR",
      "C: morphine (IV) 1–2 mg/minute dilute 10 mg up to 10 mL with sodium chloride solution",
      "0.9%. Total maximum dose: 10 mg, repeat after 4 hours if necessary.",
      "Anti-platelets therapy",
      "A: acetylsalicylic (PO) 300mg stat then followed by 75mg/100mg (PO) 24hourly",
      "AND",
      "D: clopidogrel (PO) 300mg/600mg stat then followed by 75mg 24hourly",
      "OR",
      "S: prasugrel (PO) 60mg stat, given after defining coronary anatomy prior to onset of PCI,",
      "then 10mg as maintenance dosage.",
      "Statin high dose",
      "B: atorvastatin (PO) 80mg start then 40mg 24hourly",
      "OR",
      "S: rosuvastatin (PO) 10mg-40mg 24hourly",
      "Anticoagulant",
      "B: heparin UFH (IV) 70–100U/Kg 24hourly",
      "OR",
      "S: low molecular weight heparin (SC) 1mg/kg 12hourly, Reduce dose in renal failure patient",
      "to 0.5mg/kg",
      "Beta blocker (ß –blockers)",
      "In case of LV dysfunction",
      "C: carvedilol (PO) initial dose 6.25mg 12hourly daily preferred, titrate dose upward to",
      "maximum dose 25mg hourly daily",
      "In the settings of normal systolic function",
      "B: atenolol (PO) 12.5mg or 25mg or 50mg 24hourly",
      "OR",
      "S: metoprolol tartrate (IV) 5mg 2min for max 3doses, then (PO) 50-100 mg 12hourly",
      "OR",
      "447",
      "C: metoprolol succinate (SR) (PO) 25 – 200mg 24hourly",
      "OR",
      "S: bisoprolol (PO) 2.5mg – 10mg 24hourly",
      "OR",
      "S: verapamil SR (PO) 240 mg – 480 mg daily in 1-2 divided doses",
      "Note",
      "Verapamil SR should be initiated from 7 days’ post myocardial infarction; any single dose should",
      "not exceed 240mg as secondary prevention of myocardial infarction.",
      "Angiotensin-Converting Enzyme Inhibitors (ACEIs)",
      "B: captopril (PO) 6.25mg or 12.5mg 8hourly",
      "OR",
      "C: enalapril (PO) 10mg 12hourly",
      "OR",
      "C: lisinopril (PO) 5mg-10mg 24hourly",
      "Definitive management of STEMI – Reperfusion therapy (Myocardial reperfusion)",
      "Myocardial reperfusion with rapid recanalization of infarct related artery is the key to success in the",
      "management of ST Elevation Myocardial Infarction (STEMI). Timely reperfusion is crucial for",
      "minimization of infarct size and thereby for preservation of left ventricular function and reduction in",
      "mortality in STEMI patients. The two main reperfusion strategies for STEMI patients are;",
      "•",
      "Thrombolytic/Fibrinolytic therapy (preferably chest pain duration less 12 hrs)",
      "•",
      "Primary percutaneous coronary intervention (PPCI) (preferably less than 90 mins of Door to",
      "Needle Time)",
      "Thrombolytic agents",
      "S: streptokinase (IV) 1.5 million units diluted in 100 mL sodium chloride 0.9%, infused over",
      "30–60minutes",
      "OR",
      "S: alteplase (TPA) (IV) 15mg as bolus, 0.75mg/kg over 30min, then 0.5mg/kg over 60min",
      "Absolute contraindication for Thrombolytics",
      "•",
      "Previous allergy to streptokinase or used within the last year for streptokinase only.",
      "•",
      "Stroke CVA within the last 3 months",
      "•",
      "History of recent major trauma",
      "•",
      "Bleeding within the last month",
      "•",
      "Aneurysms",
      "•",
      "Brain or spinal surgery or head injury within the preceding month",
      "•",
      "Active bleeding or known bleeding disorder.",
      "Relative contraindication for Thrombolytics",
      "•",
      "Refractory hypertension",
      "•",
      "TIA in the preceding 6 months,",
      "•",
      "Subclavian central venous catheter",
      "•",
      "Warfarin therapy",
      "•",
      "Pregnancy",
      "•",
      "Traumatic resuscitation",
      "•",
      "Recent retinal laser treatment",
      "Referral is urgent for all suspected or diagnosed cases to high level care equipped with cardiac",
      "catheterization laboratory for Coronary angiogram (CAG) followed by Percutenous Coronary",
      "Intervention (PCI)."
    ]
  },
  {
    "section_code": "20.5",
    "condition": "Hypertension",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.6",
    "condition": "Resistant (Refractory) Hypertension",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.7",
    "condition": "Hypertensive Urgency",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.8",
    "condition": "Hypertensive Emergency",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.9",
    "condition": "Heart Failure",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Oxygen therapy and/or ventilatory support.",
      "•",
      "Non-invasive positive pressure ventilation includes both CPAP and bi–level positive",
      "pressure ventilation (PPV)",
      "•",
      "Mechanical ventilation",
      "Note",
      "In AHF, oxygen should not be used routinely in non–hypoxaemic patients, as it causes",
      "vasoconstriction and a reduction in cardiac output",
      "Pharmacological treatment",
      "Recommendations for the management of patients with acute heart failure:"
    ]
  },
  {
    "section_code": "20.10",
    "condition": "Chronic Heart Failure",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.11",
    "condition": "Pulmonary Oedema",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.12",
    "condition": "Infective Endocarditis (IE)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.13",
    "condition": "Acute Rheumatic Fever",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.14",
    "condition": "Pulmonary Embolism",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "3.0",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.5",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.0",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "1.0",
    "condition": "points",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.14.2",
    "condition": "Chronic Pulmonary Embolism",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15",
    "condition": "Cardiac Arrhythmias/ Dysrhythmias",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15.1",
    "condition": "Tachyarrythmias",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15.2",
    "condition": "AV Junctional Re-Entry Tachycardias",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.15.3",
    "condition": "Wide QRS (Ventricular) Tachyarrhythmias (VTs)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.16",
    "condition": "Heart Block (Second and Third Degree)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.17",
    "condition": "Sinus Bradycardia & Sinus Arrest",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1",
    "condition": "Chronic Kidney Diseases (CKD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.1",
    "condition": "g/mmol OR ACR (albumin-creatinine ratio) > 100 g/mol, confirm as positive if raised on at least 2",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.2",
    "condition": "Hypertension and CKD",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.3",
    "condition": "Dialysis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.4",
    "condition": "CKD Associated Metabolic Acidosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "6.5",
    "condition": "and Severe >6.5. Severity grading increases once there is ECG changes.",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.6",
    "condition": "CKD Associated Anaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.7",
    "condition": "Mineral Bone Disease (MBD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.1.8",
    "condition": "Haemodialysis (HD) Catheter Related Blood Stream Infection",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.2",
    "condition": "Acute Kidney Disease",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.3",
    "condition": "Glomerular Diseases (GD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.3.1",
    "condition": "Glomerular disease - Nephritic syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.3.2",
    "condition": "Nephrotic syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.4",
    "condition": "Kidney Transplantation",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.4.3",
    "condition": "Transplant Recipient",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.5",
    "condition": "Cystic Kidney Disease",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.6",
    "condition": "Renal artery stenosis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.8",
    "condition": "Reflux nephropathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.9",
    "condition": "Contrast Induced Nephropathy (CIN)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10",
    "condition": "Urinary Tract Infection (UTI)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10",
    "condition": "Urology Disorders",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.1",
    "condition": "Prostatitis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.4",
    "condition": "Urolithiasis",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.10.5",
    "condition": "Obstructive uropathy",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.11",
    "condition": "Sexual Dysfunction",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "21.11.2",
    "condition": "Male sexual dysfunction",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.1",
    "condition": "Cancer Prevention, Screening and Early Detection",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2",
    "condition": "Gynecological Malignancies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "2.5",
    "condition": "Gy to 50 Gy external beam only no HDR nor chemotherapy if poor",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.2",
    "condition": "Endometrial Cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.2.3",
    "condition": "Cancer of the Vulva",
    "definition": "",
    "investigations": [
      "•",
      "Serum β-hCG level",
      "•",
      "LFT, RFT, TSH, T3, T3",
      "•",
      "CXR and or CT Scan chest",
      "•",
      "Abdomen and Pelvis USS or CT Scan",
      "•",
      "Brain MRI",
      "•",
      "Tissue sample for histology",
      "•",
      "CSF hCG level",
      "•",
      "PET/CT",
      "Clinical presentation:",
      "•",
      "Persistently raising or plateau BhCG postmolar pregnancy."
    ],
    "treatment": [
      "Treatment is individualized, taking into considerations of histological type, disease stage and patient",
      "factors",
      "Primary treatment is surgery. Wide Local Excision (Radical Vulvectomy) plus Groin Lymphnode",
      "dissection.",
      "Radiotherapy is indicated in the following conditions:",
      "•",
      "As primary therapy for patient with small primary tumors particularly young patients in",
      "whom surgical resection would have significant psychological consequences.",
      "•",
      "For patients with locally advanced disease where resection is not possible.",
      "`503",
      "•",
      "After surgery to treat the pelvic and groin nodes.",
      "•",
      "After surgery in patients with positive surgical margins.",
      "•",
      "In palliation (Pain, Bleeding etc)",
      "Pharmacological Treatment: As for cervical cancer",
      "22.2.4.    Gestational Trophoblastic Disease",
      "22.2.4.1 Hydatidiform mole",
      "Two types; complete and partial hydatidiform mole. Treatment is suction curettage or hysterectomy.",
      "Careful risk assessment is needed to determine patients who require chemotherapy after surgery.",
      "Patient with high risk hydatidiform mole will have to reserve single agent chemotherapy;",
      "methotrexate or actinomycin D"
    ]
  },
  {
    "section_code": "22.2.5",
    "condition": "Cancer of the Ovary",
    "definition": "",
    "investigations": [
      "•",
      "Inspection and bimanual examination under anesthesia (EUA) recto–vagina are mandatory",
      "to exclude primary disease or extension from other sites such as cancer of the cervix",
      "•",
      "FBC, RFT, LFT, CA 125 & CEA",
      "•",
      "CXR",
      "•",
      "Abdomen and Pelvis CT Scan or USS",
      "•",
      "Histology of Oophorectomy specimen or biopsy obtained at laparotomy",
      "•",
      "Ascitic fluid/peritoneal and pelvic washing cytology"
    ],
    "treatment": [
      "Surgery",
      "Stage 1 and 2",
      "Total hysterectomy with Bilateral Salpingo –Oophorectomy (TAH+BSO) and",
      "omentectomy should be performed in resectable tumor.",
      "If total tumor removal is not possible, then maximum debulking (Cyto –",
      "reductive) surgery is done. This is followed by adjuvant Chemotherapy.",
      "Unilateral salpingo-oophorectomy is only justified for stage IA tumour with",
      "favourable histology.",
      "Stage 3",
      "Neoadjuvant chemotherapy followed by Surgery and then Adjuvant",
      "Chemotherapy.",
      "Stage 4",
      "As stage 3 +/- Palliative care.",
      "Pharmacological Treatment",
      "Adjuvant chemotherapy",
      "Indicated in all patients at high risk i.e. stage IC or II, high grade or clear cell cancers of any stage.",
      "Recommended regimens is;",
      "S: carboplatin (IV) AUC 6  1 hour infusion Day 1 AND  paclitaxel (IV) 175 mg/m2 over 3",
      "hours day1; repeat every 21days for 6 cycles.",
      "For recurrent disease: give same regimen if tumor is platinum sensitive (recurrence after 6 months",
      "since last chemotherapy cycle)",
      "For platinum resistant disease give gemcitabine or bevacizumab as single agent or in combination",
      "with taxanes. When available, liposomal doxorubicin is active and indicated in recurrent disease.",
      "S: gemcitabine (IV) 1000 mg/m2  30 minutes infusion Day 1, Day 8 and Day 15;",
      "Repeat every 4 weeks for 6 Courses",
      "S: bevacuzimab (IV) 15 mg/kg 1-hour infusion Day1, every 3 weeks until",
      "disease progression",
      "Endocrine therapy is indicated in selected cases with recurrent disease.",
      "S: tamoxifen (PO) 20mg every 12 hourly,daily AND goserelin (SC) 3.6 mg",
      "every 4 weeks or 10.8mg every 12 weeks",
      "Note",
      "All patients must be referred to a gynecologist and cancer specialized center for evaluation and",
      "proper management",
      "`506"
    ]
  },
  {
    "section_code": "22.3",
    "condition": "Breast Cancer",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Includes surgery, chemotherapy, radiotherapy, hormonal therapy and targeted",
      "therapy",
      "Surgery",
      "Optimal management includes multidisplinary evaluation by clinical oncologist and breast surgeon.",
      "Options for surgical management include:",
      "•",
      "Breast conserving surgery with lumpectomy/quadrantectomy",
      "•",
      "Modified radical mastectomy",
      "•",
      "Toilet Mastectomy",
      "As described above, all surgical approaches should include surgical axillary staging with axillary",
      "lymph node dissection to level 1 and 2 nodes (>10 lymph nodes dissected).",
      "Surgical approaches aimed at breast conservation should only take place in cases that allow for",
      "multi-disciplinary management with access to radiotherapy. If radiotherapy access is limited,",
      "mainstay of surgical care should be modified radical mastectomy.",
      "Radiotherapy is strongly indicated in the following conditions:",
      "•",
      "After BCS",
      "•",
      "T3–4 tumor",
      "•",
      "Positive surgical margin",
      "•",
      "If ≥ 4 sampled lymphnodes are positive",
      "•",
      "Palliation for fungating and bleeding tumor, mets to bones, brain etc.",
      "`507",
      "Radiotherapy dose: 50Gy/25 Fractions given in 5 weeks or Hypofractionation 40.05Gy/15",
      "Fractions. For palliative intent usually 30Gy/10 Fractions in 2 weeks",
      "Pharmacological Treatment",
      "Chemotherapy is indicated for almost all patients as neo-adjuvant, adjuvant or palliative. Patients,",
      "who are planned for surgery and have ≥ T3 tumors, should receive neo-adjuvant chemotherapy",
      "before operation.",
      "Table 22.8 Recommended chemotherapy regimens for Breast cancer",
      "Dosing schedules for combinations for HER 2 negative disease:",
      "1",
      "Dose-dense doxorubicin (IV) AND cyclophosphamide(IV) followed by weekly paclitaxel (IV)",
      "S: doxorubicin (IV) 60 mg/m2 over 30 minutes’ day 1 AND cyclophosphamide (IV) 600 mg/m21-hour",
      "infusion day 1 given every 14 days for 4 cycles",
      "Followed by",
      "S: paclitaxel (IV) 80 mg/m2 by 1-hour infusion weekly for 12 weeks.",
      "2",
      "Dose-dense adriamycin AND cyclophosphamide followed by 3 weekly taxanes",
      "S: doxorubicin 60 mg/m2 (IV) over 30 minutes on day 1 PLUS cyclophosphamide 600 mg/m2 1 hour",
      "(IV) infusion day 1 given every 21 days for 4 cycles then",
      "Followed by",
      "S: paclitaxel (IV) 175 mg/m2 3 hours infusion day 1, given every 21days for 4 cycles",
      "OR",
      "S: docetaxel (IV) 100 mg/m2 3 hours infusion day 1 given every 21days for 4 cycles.",
      "3",
      "TAC (IV) chemotherapy regimen",
      "S: docetaxel (IV) 75 mg/m2 3 hours’ infusion day 1 AND doxorubicin (IV) 50 mg/m2 30 minutes’ day",
      "1 AND cyclophosphamide (IV) 500 mg/m2 1-hour infusion day 1 given every 21 days for 6 cycles.",
      "Dosing schedule for combinations for HER2-Positive disease:",
      "1",
      "S:  doxorubicin (IV) 60 mg/m2 30 minutes’ day 1 AND cyclophosphamide (IV) 600 mg/m2 1-hour",
      "infusion day 1 given every 21 days for 4 cycles followed by paclitaxel (IV) 80 mg/m2 1-hour infusion",
      "weekly for 12 weeks",
      "AND",
      "S:  trastuzumab (IV) 4 mg/kg with first dose of paclitaxel (IV) followed by trastuzumab (IV) 2 mg/kg",
      "weekly to complete 1 year of treatment.",
      "2",
      "As an alternative, trastuzumab (IV) 6 mg/kg (IV) every 21 days may be used following the",
      "completion of paclitaxel (IV) and given to complete 1 year of trastuzumab (IV) treatment.",
      "Note",
      "•",
      "All cycles are with myeloid growth factor support.",
      "•",
      "FBC, RFT, LFT before each cycle.",
      "•",
      "Cardiac monitoring at baseline, 3, 6, and 9 months.",
      "Other Regimens are:",
      "S: CAF (cyclophosphamide, adriamycin and 5-flourouracil)/",
      "S: CEF (cyclophosphamide, epirubicin and 5-fluorouracil) and",
      "S: CMF (cyclophosphamide, methotrexate and 5-fluorouracil) (for elderly patients>65 yrs",
      "with poor cardiac function)",
      "`508",
      "For Metastatic Breast Cancer (Stage 4):",
      "Chemotherapy regimens for either combinations ie",
      "S: CAF, CEF, gemcitabine/paclitaxel,",
      "S: trastuzumab+paclitaxel/carboplatin or trastuzumab+paclitaxel or trastuzumab +",
      "docetaxel or trastuzumab+capecitabine; or single agent",
      "S: trastuzumab, taxane or capecitabine or gemcitabine.",
      "Endocrine therapy",
      "Premenopausal ER/PR Positive",
      "S: tamoxifen (PO) 20 mg daily for 5 years",
      "Post-menopausal ER/ PR Positive",
      "S: anastrazole (PO) 1 mg daily for 5 years",
      "OR",
      "S: tamoxifen (PO) 20 mg daily for 2 years followed anastrazole (PO) 1 mg daily for 3",
      "years.",
      "Note",
      "● All patients must be referred to a specialized oncology center for proper management"
    ]
  },
  {
    "section_code": "22.4",
    "condition": "Cancer of The Skin",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.4.1",
    "condition": "Non-melanoma Skin Cancers",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.4.2",
    "condition": "Malignant Melanoma",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Surgery is the primary treatment.",
      "•",
      "Wide local excision and graft",
      "•",
      "Amputation sometimes for advanced useless limb",
      "Pharmacological Treatment",
      "S: cisplatin (IV) 20mg/m2/day 30 minutes’ infusion day 1-4 AND vinblastine (IV)",
      "1.6mg/m2/day bolus day 1-5 AND dacarbazine (IV) 800mg/m2 30minutes infusion day 1",
      "repeat every 21 days for 6 cycles",
      "OR",
      "S: dacarbazine (IV) 250mg/m2 30 minutes’ infusion Day1–Day 5 every 21 days",
      "for 4 cycles",
      "OR",
      "S: temozolomide (PO) 200mg/m2 Day 1–Day 5 every 28 days",
      "Radiotherapy used for palliation if:",
      "•",
      "Lesion is inoperable. May use large fractions: 30Gy/6Fractions/1 week",
      "•",
      "Excision margins are involved or very close",
      "•",
      "Palliative intent 30Gy in 10 Fractions/ 20Gy in 5 Fractions (brain mets, fungation or profuse",
      "bleeding, bone pain etc)"
    ]
  },
  {
    "section_code": "22.4.3",
    "condition": "Kaposi’s sarcoma (KS)",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Treatment is palliative irrespective of type and stage hence careful assessment and",
      "decision is required to choose the best palliative treatment.",
      "•",
      "ARVs should be initiated in epidemic KS patients who have not started the treatment.",
      "•",
      "Choice of palliation depends on clinical presentation and patient general condition."
    ]
  },
  {
    "section_code": "22.5",
    "condition": "Head and Neck Cancers",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.1",
    "condition": "Nasopharyngeal Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, RFT, LFT and HIV",
      "•",
      "CXR",
      "•",
      "Abdominal ultrasound",
      "•",
      "CT scan and/or MRI of the nasopharynx, skull base, and neck",
      "•",
      "Nasopharyngoscopy",
      "•",
      "Endoscopic guided biopsy of the primary tumor for histology",
      "•",
      "PET CT",
      "•",
      "Immunohistochemistry to further confirm the diagnosis"
    ],
    "treatment": []
  },
  {
    "section_code": "22.5.2",
    "condition": "Laryngeal Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, RFT and LFT",
      "•",
      "CXR",
      "•",
      "CT scan and/or MRI of the Head and Neck",
      "•",
      "Laryngoscopy",
      "•"
    ],
    "treatment": []
  },
  {
    "section_code": "22.5.3",
    "condition": "Hypopharyngeal Cancers:",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.5.4",
    "condition": "Salivary Gland Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, and RFT",
      "•",
      "CXR",
      "•",
      "CT scan and/or MRI of Head and Neck",
      "•",
      "Biopsy of the primary tumor for histology."
    ],
    "treatment": [
      "•",
      "Complete surgical resection with adjuvant radiotherapy if adverse features are present",
      "•",
      "If disease is not resectable, definitive radiotherapy or concurrent chemoradiotherapy is",
      "indicated",
      "•",
      "Neck dissection is indicated for high-grade tumors or clinically positive neck disease"
    ]
  },
  {
    "section_code": "22.5.5",
    "condition": "Nasal Cavity and Paranasal Sinus Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, RFT and LFT",
      "•",
      "CXR",
      "•",
      "Abdominal Ultrasound",
      "•",
      "CT scan and/or MRI of the Para nasal sinuses and neck",
      "•",
      "Direct fibre-optic endoscopy",
      "•",
      "Endoscopic guided biopsy of the primary tumor for histopathology"
    ],
    "treatment": [
      "•",
      "Treatment is by surgery and or radiotherapy with or without chemotherapy.",
      "•",
      "Surgical resection of the primary tumor and neck dissection followed by radiotherapy can",
      "be done in early disease stages. It may also be used for management persistently",
      "enlarged lymph nodes, persistent or recurrent disease after radiotherapy.",
      "•",
      "Stage I–IINO: Complete surgical resection followed by radiotherapy alternatively definitive",
      "radiotherapy.",
      "•",
      "Radiotherapy can be given as an alternative definitive treatment, either alone or in",
      "combination with chemotherapy. It is used in palliative care for advanced diseases",
      "•",
      "Chemotherapy is used in induction, concurrent or adjuvant therapy."
    ]
  },
  {
    "section_code": "22.5.6",
    "condition": "Oral Cavity Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, RFT and HIV",
      "•",
      "CXR",
      "•",
      "CT Scan and/or MRI of the Head and Neck",
      "•",
      "Mirror and fibre-optic endoscopic examination",
      "•",
      "Biopsy for histologic confirmation"
    ],
    "treatment": [
      "Surgery is the mainstay treatment modality for cancer of the oral cavity. Single modality treatment",
      "with surgery or radiation therapy is preferred for early-stage oral cavity cancer.",
      "Definitive radiation with concurrent chemotherapy is the current standard for unresectable locally",
      "advanced disease. Radiotherapy can be given as palliative treatment to primary or metastatic area.",
      "Chemotherapy may also be given as palliative care in a very advanced disease."
    ]
  },
  {
    "section_code": "22.5.7",
    "condition": "Oropharyngeal Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, RFT and HIV",
      "•",
      "CXR",
      "•",
      "CT Scan and/or MRI of the Head and Neck",
      "•",
      "Mirror and fibre-optic endoscopic examination",
      "•",
      "Biopsy for histologic confirmation"
    ],
    "treatment": [
      "Oropharyngeal cancers are mainly treated by Radiotherapy in combination with chemotherapy.",
      "Surgery can be used in selected cases.",
      "Table 22.11 Recommended Radiotherapy and Chemotherapy treatment for Head and Neck",
      "tumours",
      "Curative radiotherapy",
      "Radiotherapy dose for head and neck cancers is 66–70Gy given at",
      "conventional fraction of 1.8–2Gy/fractions.",
      "Concurrent Chemotherapy",
      "S: cisplatin (IV) 40mg/m2 1hour infusion weekly during Radiotherapy",
      "OR",
      "S: cisplatin (IV) 75mg/m2 1 hour infusion day 1 repeat every 21 days",
      "during radiotherapy.",
      "Induction Chemotherapy",
      "For patients with Advanced Head and Neck Cancers - PF or TPF (taxane,",
      "platinum and 5 FU) for 3 – 6 cycles.",
      "S: carboplatin (IV) AUC 5 1hour infusion day 1 AND 5-flourouracil (IV)",
      "400mg/m2 bolus day 1 AND paclitaxel (IV) 175mg/m2 3 hour infusion day",
      "1 repeat every 21 days for 3-6 cycles.",
      "Adjuvant Chemotherapy:",
      "In curative intent concurrent chemoradiotherapy is indicated with",
      "cisplatin/5FU (IV) If induction chemotherapy was not given then adjuvant",
      "chemotherapy is recommended. Alone or in combination with cetuximab.",
      "S: carboplatin (IV) AUC 5 1hour infusion day 1AND 5-flourouracil (IV)",
      "400mg/m2 bolus day 1 AND Cetuximab (IV) 400mg/m2 2 hours infusion",
      "day 1 (to be administered 1 hour before cisplatin/5-Fu) (IV) every 21 days",
      "for 3-6 cycles.",
      "Treatment of Recurrent or",
      "Metastatic disease",
      "Combination therapy cisplatin or carboplatin/docetaxel or paclitaxel.",
      "paclitaxel/ cisplatin/ 5-FU cisplatin/ gemcitabine, gemcitabine/ vinorelbine,",
      "carboplatin, cetuximab (IV).",
      "Single agents cisplatin, carboplatin, paclitaxel, docetaxel, 5-FU,",
      "methotrexate, gemcitabine and capecitabine (IV)",
      "`514",
      "Note",
      "•",
      "Head and neck tumour patients must be referred to cancer specialized centers for",
      "evaluation and definitive management. Follow up visits: 1st visit at 4–6weeks then after",
      "each 3–4 months in the 1st year, 6 monthly in the 2nd year thereafter yearly."
    ]
  },
  {
    "section_code": "22.5.8",
    "condition": "Thyroid Carcinoma",
    "definition": "",
    "investigations": [
      "•",
      "Thyroid function tests (T3, T4, TSH), FBC, LFTs, Urea & Creatinine, Serum calcitonin,",
      "Serum thyroglobulin levels",
      "•",
      "Thyroid Scan",
      "•",
      "CXR",
      "•",
      "Isotope bone scan",
      "•",
      "CT Scan of the neck",
      "•",
      "Biopsy or Fine needle aspiration cytology (FNAC) of a thyroid lesion"
    ],
    "treatment": [
      "Surgery is the mainstay of treatment; lobectomy, total or near total thyroidectomy. Radiotherapy is",
      "indicated in all cases of anaplastic carcinoma.",
      "Pharmacological Treatment",
      "•",
      "Radioactive iodine I-131 sodiumor potassium iodide ablation is indicated in all patients with",
      "well differentiated thyroid cancer after surgery.",
      "•",
      "Post ablation; Thyroid-stimulating hormone (TSH) suppression therapy (levothyroxine) is",
      "indicated in all patients post ablation and post-lobectomy.  Aim is to keep TSH <0.1mU/L.",
      "•",
      "Tumor recurrence or metastasis: Local reccurence should be managed surgically. Local",
      "reccurence or distant metastases not suitable for surgery that are iodine avid are treated",
      "with I-131.",
      "•",
      "Palliative chemotherapy is indicated for patients with visceral metastatic diseases not",
      "responding to I-131. Recommended regimen is:",
      "S: pacliataxel (IV) 175mg/m2  3 hours infusion day 1 AND doxorubicin (IV)",
      "60mg/m2 bolus day1 every 3 weeks up to 6 cycles.",
      "•",
      "Radiotherapy is indicated for Adjuvant treastment to the thyroid bed post surgery with",
      "macro/microspopic residual disease, in unresectable and local reccurence that does not",
      "take up I-131 and palliation of bone and brain metastasis. Palliative dose: 30Gy in 10",
      "Fractions.",
      "•",
      "For anaplastic carcinoma radiation is indicated and dose recommended 50-60Gy in 20-30",
      "Fractions.",
      "•",
      "Medullary Thyroid Tumor (MTC) is primarily managed by surgery, Radiotherapy",
      "•",
      "Anaplastic Thyroid Cancer (ATC) is aggressive disease. A Total thyroidectomy followed by",
      "adjuvant radiotherapy is indicated to resectable disease. If unresectable ATC palliative",
      "radiotherapy",
      "and",
      "combination",
      "chemotherapy",
      "is",
      "indicated.",
      "The",
      "recommended",
      "chemotherapy regimen is as above in metastatic disease."
    ]
  },
  {
    "section_code": "22.6",
    "condition": "Gastrointestinal Malignancies",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Surgery and radiotherapy",
      "Surgery is a major component of treatment for resectable disease. Surgery and or radiotherapy may",
      "be curative in early diseases. However, most patients present in late stages, hence the goal of",
      "treatment is to prolong survival and relieve symptoms. Radiation (alone or in combination with",
      "chemotherapy) is given as a definitive, preoperative, postoperative therapy or palliative setting.",
      "Chemotherapy",
      "Table 22.12 Recommended chemotherapy regimens for neo-adjuvant, adjuvant or palliative",
      "for Esophageal cancer",
      "Neoadjuvant Chemotherapy",
      "S: paclitaxel (IV) 175 mg/m",
      "2 3hours’ infusion day 1 AND cisplatin (IV)",
      "75 mg/m",
      "2 1-hour infusion day 1 OR carboplatin (IV) AUC 5 1-hour",
      "infusion day 1 given every 21 days for 6 cycles",
      "OR",
      "S: docetaxel (IV) 75mg/m",
      "2 3hours’ infusion day 1 AND cisplatin (IV)",
      "75mg/m",
      "2 1-hour infusion day 1 every 3 21 days for 6 cycles",
      "Adjuvant Chemotherapy",
      "S: 5–FU (IV) 1000 mg/m",
      "2  (IV) bolus day 1–day 5 AND  cisplatin (IV)",
      "75 mg/m",
      "2  1 hour  infusion day1 given every 21 days for 6 cycles",
      "Palliative Chemotherapy",
      "S: capecitabine (PO) 1000mg/m",
      "2 12 hourly on day 1–14, cycled every",
      "21 days for 6 cycles or until disease progression or intolerable toxicity",
      "Note",
      "•",
      "All patients should be referred to cancer specialized centers for proper management",
      "Stenting, gastrostomy tube and parenteral nutrition are employed to provide feeding",
      "when there is total dysphagia."
    ]
  },
  {
    "section_code": "22.6.2",
    "condition": "Gastric Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, RFT",
      "•",
      "Stool for occult blood",
      "•",
      "Carcinoembryonic antigen (CEA)_",
      "•",
      "IHC – Her 2 Status",
      "•",
      "CXR",
      "•",
      "Barium meal (double contrast)",
      "•",
      "Abdomen and pelvis CT scan or USS",
      "•",
      "Endoscopy and biopsy for histology"
    ],
    "treatment": [
      "Surgery is the primary treatment for early stage gastric cancer. Total or partial gastrectomy is",
      "performed together with lymph node dissection. By pass surgery is done to relieve obstructive",
      "symptoms. Surgery is usually preceeded by Chemotherapy (Perioperative) or adjuvant",
      "chemoradiotherapy.",
      "Pharmacological Treatment",
      "Table 22.13 Recommended chemotherapy regimens for Gastric cancer",
      "Perioperative",
      "chemotherapy",
      "S: 5-fluorouracil (IV) 500mg/m2 bolus day 1 AND epirubicin (IV) 50mg/m2 30",
      "minutes’ infusion day 1 AND cisplatin (IV) 60mg/m2 1-hour infusion day 1, cycled",
      "every 21 days for 6 cycles.",
      "OR",
      "S: capecitabine (PO) 625mg/m2 12 hourly daily for 21 days AND epirubicin (IV)",
      "50mg/m2 30 minutes’ infusion day 1 AND cisplatin (IV) 60mg/m2 1-hour infusion day",
      "1, cycled every 21 days for 6",
      "cycles.",
      "OR",
      "S: 5-fluorouracil (IV) 200mg/m2/day Continous infusion day 1-4 AND epirubicin (IV)",
      "50mg/m2 30 minutes’ infusion day 1 AND cisplatin (IV) 60mg/m2 1-hour infusion day",
      "1, cycled every 21 days for 6 cycles.",
      "locally advanced",
      "and metastatic",
      "gastric",
      "adenocarcinoma.",
      "S: paclitaxel (IV) 175mg/m",
      "2 3hours’ infusion AND carboplatin (IV) AUC 5 1-hour",
      "infusion on day 1, cycled every 21 days for 6 cycles AND/OR trastuzumab (IV)",
      "6mg/m2 2hours loading dose day1, and then 4mg/m2 every 14 days (For Her 2 +",
      "Patients).",
      "OR",
      "S: docetaxel (IV) 60mg/m",
      "2 2 hours’ infusion day 1 AND cisplatin (IV) 60mg/m",
      "2 1 1",
      "hourday1 + 5–FU (IV) 750mg/m",
      "2 continuous infusion over 24 hours on day1–4,",
      "cycled every 21 days for 6 cycles AND/OR trastuzumab (IV) 6mg/m2 2hours’",
      "infusion loading dose day1, and then 4mg/m2 every 14 days (For Her 2 + Patients).",
      "Palliative setting",
      "S: capecitabine (PO) 1000mg/m",
      "2 12 hourly on day 1–14, cycled every 3 weeks, 6",
      "cycles or until disease progression or intolerable toxicity.",
      "Note",
      "•",
      "Concurrent Chemo radiotherapy with 3DCRT may be used as adjuvant post surgery.",
      "•",
      "Radiotherapy can also be used in palliative setting to control bleeding and pain.",
      "•",
      "Gastric (MALT) lymphoma are associated with Chronic H. pylori inflammation. They are",
      "managed by H. pylori eradication and Chemoradiotherapy (see details in Lymphoma",
      "section).",
      "•",
      "Patients with CD 117 positive gastro intestinal stromal tumor (GIST) respond well to",
      "imatinib."
    ]
  },
  {
    "section_code": "22.6.3",
    "condition": "Hepatocellular Carcinoma",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.4",
    "condition": "Rectal Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, RFT, LFT, CEA",
      "•",
      "Stool for occult blood",
      "•",
      "CXR",
      "•",
      "Barium enema (double contrast)",
      "•",
      "Abdomen and Pelvis USS",
      "•",
      "Digital rectal examination",
      "•",
      "Sigmoidoscopy or Colonoscopy with Biopsy of the lession",
      "•",
      "Abdomen and Pelvis CT Scan"
    ],
    "treatment": []
  },
  {
    "section_code": "22.6.5",
    "condition": "Colon Cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.6.6",
    "condition": "Anal Cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.7",
    "condition": "Lung Cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.7.1",
    "condition": "Non-small cell lung Cancer",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, Urea, Creatinine",
      "•",
      "CXR PA & lateral views",
      "•",
      "CT Scan of Thorax and Abdomen",
      "•",
      "Abdominal USS",
      "•",
      "Bronchoscopy and Biopsy for histopathology",
      "•",
      "Cytology of sputum or bronchial aspirate examination"
    ],
    "treatment": [
      "Surgery (pneumonectomy or lobectomy) is curative for stage I and some stage II",
      "disease.",
      "Pharmacological Treatment:",
      "Recommended Chemotherapy regimens for adjuvant, unresectable or recurrent and metastatic",
      "disease are;",
      "S: carboplatin (IV) AUC 1-hour infusion 6 day1 AND paclitaxel (IV) 175 mg/m2 3 hours’",
      "infusion day 1 every 21 days for 6 cycles",
      "Radiotherapy",
      "With advanced radiotherapy machine and treatment technic, RT may be given for neo–adjuvant or",
      "adjuvant to surgery.  Palliative Radiotherapy is frequently used in metastatic disease to bone, spinal",
      "cord compression, brain, liver and in case of superior vena cava obstruction (SVCO), atelectasis,",
      "obstructive pneumonitis and fungating masses. Dose of 30GY/10 Fractions/2weeks gives good",
      "symptom relief.",
      "`521"
    ]
  },
  {
    "section_code": "22.7.2",
    "condition": "Small cell lung cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.8",
    "condition": "Genitourinary Malignancies",
    "definition": "",
    "investigations": [],
    "treatment": [
      "Treatment depends on disease profile (Risk stratification) and patient factors as noted above.",
      "Options include:",
      "•",
      "Watchful waiting",
      "•",
      "Active surveillance",
      "•",
      "Surgery (curative or palliative)",
      "•",
      "Radiotherapy (curative or palliative)",
      "•",
      "Hormonal therapy (chemical vs surgical castration)",
      "•",
      "Chemotherapy",
      "Surgery",
      "Early stages (Low and Interediate risk groups) can be treated with either radical prostatectomy or",
      "radical Radiotherapy with cure intent. However, surgery may cause postoperative impotence and",
      "impaired urinary control. TURP is carried out to both confirm the diagnosis and also as part of",
      "relieving obstruction.",
      "Radiotherapy",
      "Radical Radiotherapy for Adjuvant and definitive, EBRT up to 74 Gy/37 Fractions can be given using",
      "3DCRT or IMRT Techniques. Palliative radiotherapy is valuable to bone metastases, massive",
      "hematuria, spinal cord compression and brain mets,",
      "Hormonal Therapy",
      "Hormonal manipulation is by surgical or medical castration. It is carried out in patients with locally",
      "advanced or metastatic disease. Bilateral orchydectomy is a surgical hormonal manipulation and",
      "should not be regarded curative surgery.",
      "Pharmacological Treatment:",
      "S: goserelin (SC) 3.6 mg every 4 weeks or 10.8mg every 12 weeks with/ without oral",
      "bicalutamide (PO) 50mg once daily",
      "Note",
      "•",
      "Goserelin is not required after orchydectomy but patient may receive Bicalutamide.",
      "•",
      "Treatment with goserelin and bicalutamide may be given up to 2 years depending on",
      "patient condition and Prostate Specific Antigen (PSA) levels",
      "Chemotherapy",
      "Recommended chemotherapy regimens for hormonal refractory prostate cancer are:",
      "S: doctetaxel (IV) 75mg/m2 2 hours’ infusion day 1 given every 21 days for 6 cycles. It is",
      "mainly reserved in hormonal refractory prostate cancer.",
      "For Bone metastases/osteolytic/tumour induced hypercalcemia are:",
      "S: zolendronic acid (IV) 4mg over 15min given 4 Weekly",
      "Metastatic disease",
      "Life long ADT ± palliative RT ± bisphosphonates for hormone refractory disease. docetaxel and",
      "prednisone for androgen independent disease can add Carboplatin if docetaxel not working to",
      "Castrate resistant prostate cancer patients.",
      "Evaluation every 3 months (Check PSA level) Castrate resistant patients with rising PSA zoledronic",
      "acid should be given monthly. These are given together with Ca2+ and Vitamin D supplements.",
      "`523",
      "In Castrate resistant patients which did not respond to Docetaxel plus carboplatin and",
      "prednisolone, patients Abberaterone acetate with prednisolone is an option (500mg OD taken with",
      "food is highly recommended)",
      "S: abberaterone acetate (PO) 500mg one a day (Taken with food)",
      "OR",
      "S: enzalutamide (PO) 160mg daily"
    ]
  },
  {
    "section_code": "22.8.2",
    "condition": "Urinary Bladder Cancer",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.9",
    "condition": "Haematological Malignancies",
    "definition": "",
    "investigations": [
      "•",
      "CXR",
      "•",
      "Chest and abdominopelvic CT Scan",
      "•",
      "PET/CT",
      "•",
      "FBC, differential and film",
      "•",
      "Bone marrow aspirate and trephine",
      "•",
      "Immunohistochemistry (IHC)",
      "•",
      "LDH, Urea and Electrolyte, Creatinine, Albumin, Aspartate transaminase (AST), Bilirubin,",
      "Alkaline phosphatase, Serum calcium, Uric acid",
      "•",
      "Pregnancy test in females of child–bearing age",
      "•",
      "Hepatitis B and C",
      "•",
      "HIV status",
      "•",
      "Tissue Biopsy for histopathology",
      "•",
      "MUGA scan/ ECHO"
    ],
    "treatment": [
      "NHL diseases are sensitive to both chemotherapy and radiotherapy",
      "Indolent lymphoma",
      "They include Indolent B-cell lymphomas such as Follicular lymphoma, MALT lymphoma, nodal",
      "marginal zone lymphoma, splenic marginal zone lymphoma and small lymphocytic lymphoma,",
      "and Indolent T-cell lymphomas such as mycosis fungoides.",
      "Treatment",
      "Stage 1 and 2 can be treated with involved node radiotherapy or R_CHOP / R-CVP followed by",
      "radiotherapy.",
      "R-CHOP regimen:",
      "S: rituximab (IV) 375 mg/m2 3 hours’ infusion day 1 AND cyclophosphamide day1 750",
      "mg/m2 1-hour infusion AND doxorubicin (IV) 50 mg/m2 15 minutes’infusion day 1 AND",
      "vincristine (IV) 1.4 mg/m2 over 10 minutes (maximum 2mg) day1 AND prednisolone",
      "(PO) 100mg once a day, day 1–5, every 21 days for 6–8 cycles.",
      "`525",
      "Aggressive lymphoma with CD 20 positive",
      "These include Diffuse Large B-cell lymphoma (DLBCL), primary CNS lymphoma, adult Burkitt",
      "lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas."
    ]
  },
  {
    "section_code": "22.9.2",
    "condition": "Leukemia",
    "definition": "",
    "investigations": [
      "•",
      "FBC, LFT, RFT, Coagulation indices",
      "•",
      "Peripheral blood film",
      "•",
      "Bone marrow aspiration and trephine biopsy",
      "•",
      "Flow cytometry analysis, immunophenotyping, cytogenetic and molecular evaluation.",
      "•",
      "ECHO/ECG for Cardiac function evaluation.",
      "`527",
      "22.9.2.1 Acute Myeoid Leukemia (AML)"
    ],
    "treatment": [
      "The treatment of ALL is complex. The recommended regimens are;",
      "S: HYPER-CVAD/MTX-ARA-C Regimen (cyclophosphamide/mesna/vincristine/",
      "doxorubicin/dexamethasone/methotrexate/cytarabine/leucovorin) (IV)",
      "22.9.2.3 Chronic Myeloid Leukemia (CML)"
    ]
  },
  {
    "section_code": "22.9.3",
    "condition": "Multiple myeloma",
    "definition": "",
    "investigations": [
      "•",
      "FBC, RFT, LFT, Serum electrolytes",
      "•",
      "Peripheral smear",
      "•",
      "Bone marrow aspiration and trephine biopsy",
      "•",
      "Serum protein electrophoresis, urine for Bence Jones protein",
      "•",
      "Skeletal survey by X-ray, CT Scan or MRI",
      "•",
      "Serum β2 microglobulin"
    ],
    "treatment": [
      "Radiotherapy is used for pain control of lytic lesions that are refractory to systemic",
      "therapy, treatment of spinal cord compression from plasmacytoma and primary treatment of solitary",
      "plasmacytoma.Supportive treatment with blood transfusion, antibiotic, hydration and analgesia when",
      "indicated.",
      "`529",
      "Bisphosphonate therapy",
      "S: zoledronic acid (IV) 4mg once monthly for 2 years",
      "Recommended chemotherapy regimens include the following drugs in various combinations:",
      "Melphalan, Thalidomide, Lenalidomide, Bortezomib, Cyclophosphamide, Prednisolone and",
      "Dexamethasone.",
      "S: thalidomide (PO) 200mg 24hourly for 28days",
      "OR",
      "S: lenalidomide (PO) 25mg 24hourly for 21days,",
      "AND",
      "S: dexamethasone (PO) 40mg 24hourly on day 1, 8, 15, 22, repeats after every 4 weeks.",
      "OR",
      "S: bortezomib (IV) 1.3mg/m2 24hourly AND dexamethasone (PO) 40mg 24 hourly",
      "WITH/WITHOUT cyclophosphamide (PO) 300mg/m2 all on day 1,8,15,22. Repeat every 4",
      "weeks"
    ]
  },
  {
    "section_code": "22.10",
    "condition": "Central Nervous System Maligancies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.10.2",
    "condition": "Pituitary Tumors",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.10.3",
    "condition": "Gliomas",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11",
    "condition": "Oncological Emergencies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.1",
    "condition": "Superior Vena Cava Syndrome (SVCS)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.2",
    "condition": "Hypercalcaemia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.3",
    "condition": "Spinal–cord Compression",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "22.11.4",
    "condition": "Tumor Lysis Syndrome",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "20.11.5",
    "condition": "Febrile Neutropenia",
    "definition": "",
    "investigations": [
      "FBP, RFT, LFT, TFT, blood glucose, CK, urine drug screen, ECG, CT, MRI, EEG,",
      "urine and blood culture, syphilis screen, HIV, heavy metal screen, auto-antibody screen and lumbar",
      "puncture.",
      "Non-pharmacological treatment",
      "Hydration, early mobilization, close monitoring, transferal to ICU if patient deteriorates.",
      "Pharmacological treatment",
      "A: diazepam (IV/IM) 10-20mg 24hourly",
      "OR",
      "C: lorazepam (IM) 1-4mg 24hourly",
      "Note",
      "•",
      "If benzodiazepine does not work and symptoms are severe, ECT is an option",
      "23.6. Schizoaffective Disorder",
      "DSM-5 Diagnostic criteria",
      "For an individual to fulfill the diagnostic criteria, there must be the presence of solely hallucinations",
      "or delusions for at least 2 weeks in the absence of an affective episode, throughout the whole",
      "duration of the psychiatric illness. There must also have an uninterrupted period where there are",
      "prominent affective symptoms concurrent with symptoms of schizophrenia. Individuals should have",
      "symptoms fulfilling the diagnosis of an affective disorder for most of the duration of the illness.",
      "DSM-5 has specified 2 subtypes of schizoaffective disorder, which are:",
      "•",
      "Bipolar type - Whereby a manic episode is part of the entire course of the illness",
      "•",
      "Depressive type - Whereby a major depressive episode is part of the entire course of the",
      "illness",
      "Non-Pharmacological  Treatment",
      "•",
      "Family counselling and psycho-education",
      "•",
      "Cognitive Behavioural Therapy (CBT) for stabilized patients",
      "•",
      "Supportive group therapy for patients",
      "•",
      "Rehabilitation may be enhanced by assertive community programs, work assessment,",
      "occupational therapy and bridging programmes prior return to the community",
      "Pharmacological Treatment",
      "For Psychotic symptoms:",
      "A: chlorpromazine (PO) 100-1000mg in divided doses*, per day (max. dose 1000mg, per",
      "24hours)",
      "OR",
      "B: haloperidol, (PO) 1.5-6mg in divided doses*, per day (max. dose 20mg)",
      "`542",
      "For Manic subtype:",
      "A: carbamazepine (PO) 200-1000mg 24hourly, in divided dose*",
      "OR",
      "C: sodium Valproate (PO) 500-1000mg 24hourly, in divided dose*",
      "For Depressive subtype:",
      "A: amitriptyline (PO) 12.5-75 mg nocte",
      "OR",
      "S: fluoxetine (PO) 10-20 mg nocte",
      "Note",
      "•",
      "Symptoms should be monitored and medication can be tapered* divided doses: in acute",
      "phase 8hourly or 12hourly while in maintenance phase titrate to 12hourly or preferably",
      "24hourly",
      "23.7. Brief or Acute/Transient Psychotic Disorder",
      "DSM-5 Diagnostic criteria",
      "For an individual to fulfill this diagnosis;",
      "•",
      "He/she must have, for a duration of between 1 day to 1 month the following symptoms:",
      "o",
      "Delusions",
      "o",
      "Hallucinations",
      "o",
      "Disorganized speech",
      "o",
      "Grossly disorganized or catatonic behaviour",
      "•",
      "Exclude differentials like major depression or bipolar depression with psychotic features,",
      "schizophrenia and exclude the possibility of the symptoms being due to underlying",
      "substance use or medical conditions.",
      "Non-pharmacological Treatment",
      "Manage as Schizophrenia",
      "Pharmacological Treatment",
      "Manage as Schizophrenia",
      "23.8. Bipolar Mood Disorders",
      "These are lifelong mental disorders, which may have an episodic, variable courses. The presenting",
      "episodes may be manic, hypo manic, depressive or mixed. By definition, a diagnosis of bipolar",
      "disorders requires either a current or previous episode of mania or hypomania.",
      "Bipolar I Disorder Diagnostic Criteria",
      "DSM-5 specified that an individual need to have at least 1 manic episode in order to fulfill the",
      "diagnostic criteria of Bipolar I disorder.",
      "Manic Episode",
      "A manic episode is characterized by a period of time, of at least 1 week, during which the individual",
      "has persistent elevated (extreme happiness) or irritable mood and present for most of the days.",
      "In addition, the individual needs to have at least 3 (4 if mood is only irritable) of the following",
      "symptoms:",
      "•",
      "Increased self-confidence(Grandiose and/or religious delusions)",
      "•",
      "Reduction in the need for sleep",
      "•",
      "Chattier than usual, with increased pressure to talk",
      "•",
      "Racing thoughts",
      "•",
      "Easily distractible",
      "•",
      "Increase in number of activities engaged",
      "•",
      "Involvement in activities that might have a potential for serious consequences",
      "There must be marked impairments in terms of functioning with the onset of the above",
      "symptomatology.",
      "`543",
      "Non-Pharmacological Treatment",
      "•",
      "Hospitalization may be required during acute mania",
      "•",
      "Psychotherapy, usually after the manic episode has been controlled with medication",
      "•",
      "Family therapy and psycho-education of patient and family to increase compliance and",
      "knowledge of the condition",
      "•",
      "In severe cases, electroconvulsive therapy may be required.",
      "Pharmacological Treatment",
      "For Manic or Mixed Episodes",
      "For agitated and acutely disturbed patient: See section on patients with aggressive and disruptive",
      "behaviours.",
      "Maintenance therapy",
      "A: carbamazepine (PO) 600mg 24hourly in 2-3 divided doses, increase by 200mg at three-",
      "day interval up to a maximum of 2000mg",
      "OR",
      "C: sodium valproate (PO) 20 mg/kg/day in 2–3 divided doses (maximum of 2000 mg, per",
      "day)",
      "OR",
      "S: lamotrigine (PO) 600mg once a day, increase by 200mg at three-day interval up to a",
      "maximum of 2000mg",
      "Note",
      "•",
      "The option of combining two mood stabilizers at S: level should be allowed i.e. sodium",
      "valproate and Lithium carbonate",
      "Treatment for Severe Depressive Episodes in Bipolar Patients",
      "Give antidepressant in combination with mood stabilizer and antipsychotic if there is psychosis:",
      "A: amitriptyline (PO) 12.5 to 50mg nocte",
      "OR",
      "S: fluoxetine (PO) 10-20mg nocte,",
      "AND",
      "A: carbamazepine (PO) 200-400mg 12hourly, maximum 2000mg/per day",
      "OR",
      "C: sodium valproate (PO) 500-2000mg 24hourly",
      "AND",
      "A: chlorpromazine (PO) 100-1000mg 24hourly in divided doses, (max. dose 1000mg, per",
      "day)",
      "OR",
      "B: haloperidol (PO) 1.5mg –10mg 12hourly (if there is psychosis) and symptoms should be",
      "monitored, and medication to be tapered",
      "Note",
      "Do not use monotherapy antidepressants in bipolar patients.",
      "Referral",
      "Refer to the next level in the following situations:",
      "•",
      "Mixed or rapid cycling bipolar disorder",
      "•",
      "Depressive episodes in bipolar patients not responding to treatment",
      "•",
      "Manic episodes not responding to treatment",
      "23.9. Major Depressive Disorder",
      "It is a mood disorder characterized by at least 2 weeks of depressed mood and/or diminished",
      "interest and pleasure in activities. It is associated with impairment in level of functioning in different",
      "areas including social and occupational.",
      "Diagnostic Criteria",
      "Psychological symptoms",
      "•",
      "Depressed mood",
      "•",
      "Feeling of worthlessness",
      "•",
      "Guilt",
      "•",
      "Diminished concentration",
      "•",
      "Thoughts of death and suicide",
      "`544",
      "Somatic symptoms",
      "•",
      "Change in appetite",
      "•",
      "Sleep disturbances",
      "•",
      "Agitation",
      "•",
      "Retardation",
      "•",
      "Loss of energy",
      "Non-Pharmacological Treatment",
      "Effective psychotherapies include:",
      "•",
      "Cognitive Behavioural Therapy",
      "•",
      "Interpersonal psychotherapy",
      "•",
      "Stress management / coping skills",
      "•",
      "Marital and family issues",
      "•",
      "Sleep hygiene advice",
      "Pharmacological Treatment",
      "A: amitriptyline (PO) 12.5–75mg 24hourly at night, increase gradually to a maximum of",
      "150mg 24hourly. {Elderly: Initially 12.5–50 mg. Max. 75mg)",
      "OR",
      "D: citalopram (PO) 10-60mg 24hourly",
      "OR",
      "S: fluoxetine (PO) 20-60mg 24hourly (morning)",
      "Note",
      "•",
      "Efficacy of the treatment is gauged by amelioration of symptoms and the dose should be",
      "titrated according to clinical response.",
      "•",
      "Monitor all patients recently started on antidepressants closely for increased agitation and",
      "suicidal behaviour, especially young patients (younger than 25 years).",
      "•",
      "Some symptoms, such as sleep and appetite, may improve more quickly.",
      "•",
      "If partial response or non-response, increase the dose or switch to another antidepressant.",
      "The first line is an alternative SSRI. The second line is an antidepressant from a different",
      "class.",
      "Referral",
      "Refer to the next level in the following situations:",
      "•",
      "Suicidal ideation",
      "•",
      "Major depression with psychotic features",
      "•",
      "Failure to respond to available antidepressants",
      "•",
      "Patients with concomitant medical illness, e.g. heart disease, epilepsy",
      "•",
      "Poor social support systems",
      "•",
      "Pregnancy and lactation",
      "23.10. Suicide",
      "Suicide is",
      "the",
      "act",
      "of",
      "intentionally",
      "causing",
      "one's",
      "own death.",
      "Mental",
      "disorders—",
      "including depression, bipolar",
      "disorder, autism",
      "spectrum",
      "disorders, schizophrenia, personality",
      "disorders, anxiety disorders, physical disorders such as chronic fatigue syndrome, and substance",
      "abuse—including alcoholism and the use of and withdrawal from benzodiazepines—are risk",
      "factors.Some suicides are impulsive acts due to stress (such as from financial or academic",
      "difficulties),",
      "relationship",
      "problems",
      "(such",
      "as breakups or",
      "deaths",
      "of",
      "close",
      "ones),",
      "or",
      "harassment/bullying. Those who have previously attempted suicide are at a higher risk for future",
      "attempts.",
      "Effective suicide prevention efforts include;",
      "•",
      "Limiting access to methods of suicide—such as hanging, firearms, drugs, and poisons",
      "•",
      "Treating mental disorders and substance misuse",
      "•",
      "Careful media reporting about suicide",
      "•",
      "Improving economic conditions.",
      "23.11. Generalized Anxiety Disorder",
      "Generalized anxiety disorder is characterized by excessive, exaggerated anxiety and worry about",
      "everyday life events with no obvious reasons for worry.",
      "`545",
      "Diagnostic Criteria",
      "Symptoms include",
      "•",
      "Persistent worry",
      "•",
      "Disturbances in sleep",
      "•",
      "Poor concentration",
      "•",
      "Mood disturbances",
      "•",
      "Muscle tension",
      "•",
      "Tremors",
      "Non-pharmacological Treatment",
      "•",
      "Psychotherapy",
      "•",
      "Most patients can be treated as outpatients",
      "Pharmacological Treatment",
      "Indicated where symptoms are interfering with normal functions of daily living. Where there is",
      "concomitant drug/alcohol dependence or co-morbid major depressive episode, an antidepressant",
      "may be more appropriate.",
      "Acute management",
      "For an acute episode or intense prolonged anxiety:",
      "A: diazepam (PO) 2–5 mg stat repeat 12hourly when required",
      "o",
      "Duration of therapy: up to 2weeks, taper off to zero within 6weeks",
      "Maintenance Therapy",
      "A: amitriptyline (PO) 25–75mg nocte (Medication should be titrated according to symptoms",
      "resolution)",
      "OR",
      "D: citalopram (PO) 10–40mg 24hourly (Medication should be titrated according to",
      "symptoms resolution)",
      "OR",
      "D: clonazepam (PO) 0.5 – 4 mg 24hourly (Medication should be titrated according to",
      "symptoms resolution)",
      "OR",
      "S: fluoxetine (PO) 20–40mg 24hourly (Medication should be titrated according to",
      "symptoms resolution)"
    ],
    "treatment": []
  },
  {
    "section_code": "23.15.2",
    "condition": "Substance Induced Disorder",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "23.17.1",
    "condition": "Depression",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.17.2",
    "condition": "Panic Disorder",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.17.3",
    "condition": "Obsessive-Compulsive Disorder",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.17.4",
    "condition": "Bipolar Mood Disorder",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "12.17.5",
    "condition": "Schizophrenia",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.1",
    "condition": "Iodine Deficiency Disorders (IDD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.2",
    "condition": "Vitamin A Deficiency (VAD)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3",
    "condition": "Vitamin B Deficiencies",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3.2",
    "condition": "Vitamin B3/Nicotinic Acid Deficiency (Pellagra)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3.3",
    "condition": "Vitamin B6/Pyridoxine Deficiency",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.3.4",
    "condition": "Vitamin B12 (Cobalamin) Deficiency",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.4",
    "condition": "Malnutrition",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.4.1",
    "condition": "Management of Severe Acute Malnutrition (SAM)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.5",
    "condition": "Growth Faltering/Failure to Thrive",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.6",
    "condition": "Obesity and Overweight",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.7",
    "condition": "Nutritional Management in TB, HIV and AIDS",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.7.1",
    "condition": "Nutrient Requirements and Dietary Management in TB, HIV and AIDS",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.8",
    "condition": "Dumping Syndrome.",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.9",
    "condition": "Dietary Management in Diabetes Mellitus",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "24.10",
    "condition": "Nutrition Care and Support in the Intensive Care",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.1",
    "condition": "Common Poisons",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2",
    "condition": "General Principles of Management of Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.1",
    "condition": "Management Protocol of a poison (specific and non-specific antidotes)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.2",
    "condition": "Management of Ingested Poisons",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.3",
    "condition": "Food Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.4",
    "condition": "Herbal Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.5",
    "condition": "Management of Skin Contamination",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.6",
    "condition": "Management of Eye Contamination",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.2.7",
    "condition": "Management of Inhaled Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3",
    "condition": "Specific poisons",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.2",
    "condition": "Petroleum Compounds Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.3",
    "condition": "Organo-Phosphorus and Carbamate Compounds Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "7.6",
    "condition": "mL/kg of 10% EtOH solution)",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.4",
    "condition": "Paracetamol Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.5",
    "condition": "Acetylsalicylic Acid and other Salicylates Poisoning.",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.6",
    "condition": "Iron Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.7",
    "condition": "Carbon-monoxide Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.8",
    "condition": "Opioid Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.3.9",
    "condition": "Heavy Metal Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Remove from the exposure,",
      "•",
      "Airway Breathing and Circulation",
      "(ABC)",
      "•",
      "Give oxygen",
      "•",
      "Copious irrigation of the skin if skin",
      "involvement",
      "•",
      "Do",
      "gastric",
      "lavage",
      "if",
      "ingested",
      "mercury",
      "and",
      "observed",
      "in",
      "the",
      "abdominal radiographs",
      "•",
      "Do",
      "Hemodialysis",
      "when",
      "renal",
      "function has declined.",
      "Pharmacological Treatment",
      "Chelation therapy for acute inorganic mercury poisoning can be done with DMSA or",
      "Dimercaprol.",
      "Occasionally",
      "2,3-dimercapto-1-propanesulfonic",
      "acid (DMPS), D-",
      "penicillamine (DPCN).",
      "A: activated charcoal (PO) as in ingested poisons",
      "OR",
      "D: 2,3-dimercapto succinic acid (PO) (DMSA or succimer) 10 mg/kg 8 hourly  for 5 days;",
      "follow by 10 mg/kg/dose 12 hourly for 14 days; not to exceed 500 mg/dose",
      "In acute inorganic mercury poisoning:",
      "D: Dimercaprol:",
      "o",
      "Day 1: 5mg/kg deep (IM) stat",
      "o",
      "Day 2–11: 2.5mg deep (IM) 12 hourly for 10 days",
      "Surgical intervention: To remove mercury that has been logged in the intestine or colon"
    ]
  },
  {
    "section_code": "25.4",
    "condition": "Prevention of Poisoning",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.5",
    "condition": "Alcohol Intoxication",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.6",
    "condition": "Bites and Stings",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "25.6.1",
    "condition": "Management of Specific Bites/Stings",
    "definition": "",
    "investigations": [],
    "treatment": [
      "•",
      "Airway and breathing",
      "•",
      "Remove stingers by forceps or scrap with care",
      "•",
      "Elevation of the affected limb",
      "•",
      "Clean wound",
      "Pharmacological Treatment",
      "A:  adrenaline 0.5mg (IV) (0.1Ml) of 1;1000 solution diluted in 10ml of 0.9% sodium chloride",
      "slowly over 30minutes",
      "AND",
      "A: chlorpheniramine (PO) 4mg 4-6 hourly; not to exceed 24 mg/day; 8mg orally 8-12hourly",
      "or 12mg every 12hourly; not to exceed 24mg/day",
      "o",
      "Children under 2 years: Safety and efficacy not established",
      "o",
      "Children 2-6 years: 1 mg (PO) 4-6hourly; not to exceed 6mg/day",
      "o",
      "Children 6-12 years: 2mg (PO) 4-6hourly; not to exceed 12mg/day or sustained",
      "release at bedtime.",
      "o",
      "Children over 12 years: 8 mg (PO) 8-12hourly or 12 mg 12hourly; not to exceed",
      "24 mg/day",
      "OR",
      "A: promethazine (PO/Rectal) 6.25 to 12.5 mg orally or rectally before meals and at",
      "bedtime, if necessary,",
      "OR",
      "A: promethazine 25mg orally or rectally 24hourly at bedtime",
      "OR",
      "A:  promethazine 25mg (IM or IV) stat, and may be repeated within 2hours if necessary",
      "OR",
      "C: loratadine (PO) 10mg24hourly",
      "Pediatric Dose:",
      "2-5years: loratadine (PO) 5mg 24hourly (syrup)",
      "6 years or older: loratadine (PO) 10mg 24hourly (tablets, capsule, and disintegrating",
      "tablets)",
      "AND",
      "A:  0.9% sodium chloride 10–20mls/kg as a bolus",
      "AND",
      "A: paracetamol (PO) 1g for adult or 15mg/kg for children 8hourly for 48hours",
      "OR",
      "D: methylprednisolone (IV) 125mg stat inpatient with respiratory and cardiovascular",
      "compromised.",
      "Note",
      "Patient with multiple stings: observe for 24hours",
      "•",
      "Healthy adults >50stings,",
      "•",
      "Children 1 sting",
      "25.6.1.2 Scorpion Sting (Envenoming)",
      "Scorpion stings can be very painful for days. Systemic effects of venom are much more common in",
      "children than adults.",
      "Clinical Presentations",
      "•",
      "Local pain and/or paresthesia at the site of envenomation,",
      "•",
      "Pain and/or paresthesia remote from the site of sting,",
      "•",
      "Autonomic disturbances such as tachy/bradycardia, hyper/hypotension, hypersalivation and",
      "lacrimation, urinary and faecal incontinence and pulmonary oedema.",
      "•",
      "Blurred vision, roving eye movement, tongue fasculation, dysphagia, dysphonia, restless,",
      "•",
      "Severe involuntary shaking or jerking extremities",
      "•",
      "Cardiogenic shock",
      "Deaths from scorpion stings are usually due to cardiogenic shock and pulmonary oedema.",
      "Grading of Envenomation",
      "•",
      "Grade I involves local pain and paresthesias at the sting site. The puncture wound may not",
      "be noticeable in this grade.",
      "•",
      "Grade II involves local pain and paresthesias existing at the sting site as well as proximal to",
      "the sting site.",
      "•",
      "Grade III includes grade 2 classification factors with added cranial nerve (increased oral",
      "secretions, blurry vision, rapid tongue movement, nystagmus), or skeletal neuromuscular",
      "dysfunction (flailing of the extremities and tetanus-like arching of the back) and can also be",
      "accompanied by autonomic dysfunction.",
      "•",
      "Grade IV includes both 3 and hyperthermia, up to 104 ⁰F, rhabdomyolysis, pulmonary",
      "edema, and multiple organ failures.",
      "Non-pharmacological Treatment",
      "•",
      "Provide adequate airway, ventilation and perfusion",
      "•",
      "Calm the patient to lower the heart rate and blood pressure, thus limiting the spread of the",
      "venom",
      "•",
      "Give oxygen as above",
      "•",
      "Monitor vitals: oxygen saturation, heart rate respiratory rate and blood pressure",
      "Pharmacological Treatment",
      "A: Cleaning of the sting area with Normal saline",
      "AND",
      "A: compound sodium lactate (IV) 2L for 24hours",
      "AND",
      "A: adrenalin (IM) dose of 1:1000 (Repeat after 5 min if no improvement)",
      "591",
      "Children > 12 years and Adults 500 µg (0.5ml)",
      "Children 6-12 years 300 µg (0.3ml)",
      "Children < 6 years 150 µg IM (0.15ml)",
      "Intubation equipment should be made available before the administration of the antivenom in case of",
      "anaphylactic shock",
      "OR",
      "S: equine antivenom (Centruroides Scorpion) for (Grade III or IV envenomations) -",
      "intravenous scorpion-specific F(ab’)2 equine antivenom at a maximum of three vials in 20",
      "to 50 mL of normal saline and infused over 30 minutes.",
      "Initial dose: infuse 1vial of the 3vials over 10minutes, observe for 60minutes If symptoms",
      "persist you may repeat the remaining 2 vials, one vial at a 30minutes interval.",
      "AND",
      "A: paracetamol (PO) or IV 1g for adult or 15mg/kg for children (PO) 8hourly for 48hours",
      "OR",
      "A:  ibuprofen"
    ]
  },
  {
    "section_code": "0.28",
    "condition": "mg/kg",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.09",
    "condition": "mg/kg",
    "definition": "",
    "investigations": [],
    "treatment": []
  },
  {
    "section_code": "0.1",
    "condition": "mg/kg",
    "definition": "",
    "investigations": [],
    "treatment": []
  }
]